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Bone is one of the few tissues in vertebrates that possess the innate capacity for authentic 
regeneration, yet approximately 10% of fractures fail to heal adequately. There is considerable 
overlap in the cellular and molecular events occurring during embryological bone development 
and fracture repair. Mesenchymal stem cell (MSC) precursors undergo osteogenesis to give rise 
to osteoblasts, which are responsible for bone matrix synthesis and mineralization. Osteogenesis 
is regulated by two master transcription factors, runt-related transcription factor 2 (RUNX2) and 
Osterix (OSX), with interplay from signaling pathways such as the Bone Morphogenetic Protein 
(BMP) network. MSCs isolated from bone marrow (BM) and adipose tissue (ADI) are most 
commonly utilized in human and veterinary regenerative medicine applications. BM-MSCs have 
shown superior osteogenic capacity to ADI-MSCs in many studies, yet sample collection and 
culture techniques often vary between species. The overall objective of this dissertation was to 
determine factors that influence the in vitro osteogenic capacity differences of equine adult ADI- 
and BM-MSCs in order to standardize techniques and provide insights into avenues for 
improving osteogenesis in less-osteogenic MSC populations. The first study investigated the 
hypotheses that in vitro cell viability, proliferation, and osteogenic differentiation of MSCs 
collected from horses under general anesthesia and after euthanasia would be impaired compared 
to MSCs collected from horses during sedation. The second set of experiments characterized the 
RUNX2 and OSX response axes of ADI- and BM-MSCs during osteogenesis to test the 
hypotheses that 1) the relative osteogenic capacities are consistent with resting and inducible 
RUNX2 and OSX transcript levels, and 2) increasing OSX expression in ADI-MSCs improves 
their osteogenic capacity. The third series of experiments evaluated the comparative BMP 
signaling activities in ADI- and BM-MSCs to determine whether 1) osteogenic BMP ligand 
expression differs, 2) BMP inhibition in BM-MSCs impairs osteogenesis, and 3) BMP 
supplementation to ADI-MSCs improves osteogenesis. The results indicate that donor status 
during MSC collection does not affect in vitro cell viability, proliferation, and osteogenic 
capacity. BM-MSCs have higher OSX expression and intrinsic BMP signaling in both resting 
and osteogenic conditions than ADI-MSCs. Endogenous BMP activity is necessary for 
osteogenesis in BM-MSCs, and exogenous BMP supplementation, but not OSX over-expression, 
was sufficient to improve the osteogenic capacity of ADI-MSCs. In summary, OSX expression 
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Bone is one of the few tissues in the vertebrate body with the capacity for authentic 
regeneration, yet approximately 10% of fractures fail to heal due to a variety of physiological 
and mechanical factors. Bone grafting is currently considered the “gold standard” therapy in 
fracture non-union and defect management, but there are numerous limitations that warrant 
investigation into alternative modalities. Regenerative medicine typically utilizes a multi-modal 
approach, incorporating combinations of bone grafting materials, bio-scaffolds, cell-based 
therapeutics or transplantation, gene therapy, and exogenous growth factors. To date, there is no 
“one-size-fits-all” strategy to ensure uneventful fracture repair. 
MSCs have shown considerable promise in treating a variety of orthopedic conditions, 
both in human and veterinary medicine, due to their extensive proliferative ability, multi-lineage 
differentiation potential, and trophic activities. MSCs demonstrate tissue-specific lineage 
predilections, making particular sources more or less valuable for bone regenerative applications. 
Several studies have demonstrated that bone marrow-derived (BM) MSCs show superior in vitro 
and in vivo osteogenic capacity compared to adipose tissue-derived (ADI) and other MSCs. 
However, the techniques used in MSC collection, propagation, and in vitro differentiation often 
differ between species, making cross-study comparisons difficult to interpret. Therefore, there is 
a need for research into 1) optimizing MSC collection and in vitro techniques used within and 
across species, 2) identifying factors that influence the differing osteogenic potentials of MSCs 
from various sources, and 3) determining how to best enhance osteogenesis in MSC populations.  
The overall objective of this dissertation was to identify factors that influence the in vitro 
osteogenic capacity differences between equine adult ADI- and BM-MSCs. The experiments 
were designed to 1) determine the effect of donor status during sample collection on the viability, 
proliferation, and in vitro osteogenic differentiation of ADI- and BM-MSCs, and 2) characterize 
the influence of intrinsic cellular characteristics, such as expression of the master osteogenic 
transcription factors runt-related transcription factor 2 (RUNX2) and osterix (OSX) and Bone 
Morphogenetic Protein (BMP) signaling activity, on the osteogenic abilities of ADI- and BM-
MSCs. The results of the experimental studies will help to standardize sample collection and 
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culture techniques, and provide insights into approaches for improving osteogenesis in less 
osteogenically-inclined MSC populations to optimize their use in bone regenerative medicine. 
The literature review (Chapter 2) first provides an overview of skeletal development, 
osteogenic differentiation, and bone regenerative medicine approaches. The remainder of the 
literature review focuses on MSC characteristics, cross-species ADI- and BM-MSC collection 
and isolation techniques, in vitro osteogenic differentiation models, and assays for measuring 
osteogenesis in vitro. Finally, the literature review outlines comparative osteogenesis studies in 
various species, provides an overview of the current understanding of the BMP-RUNX2-OSX 
regulatory axis, and then evaluates approaches for improving osteogenesis with a specific focus 
on BMP signaling enhancement and RUNX2 and OSX over-expression. 
 The first experimental study (Chapter 3) addressed a probable cause of inter-donor 
variability in stem cell biology research by testing the hypothesis that in vitro cell viability, 
proliferation, and osteogenic differentiation of MSCs collected from donors under general 
anesthesia and after euthanasia would be impaired compared to MSCs collected from donors 
during sedation. Equine adult ADI- and BM-MSCs were collected from four healthy adult horses 
sequentially during 1) standing sedation, 2) general anesthesia, and 3) shortly after euthanasia. 
Isolated MSCs were evaluated for initial primary cell yields and population doubling times 
through three passages. Passage 3 cells were subjected to in vitro osteogenic differentiation and 
evaluated at days 5 and 10 post-osteogenic induction for multi-cellular aggregation, Alizarin Red 
staining of mineralized matrix, mRNA expression of osteogenic genes RUNX2, OSX, and 
alkaline phosphatase (ALP), and ALP enzymatic activity. Overall, MSCs collected during 
general anesthesia and after euthanasia behaved equivalently to MSCs collected during sedation. 
There was a slight effect of donor status during collection on some earlier time point analyses, 
but the differences equilibrated at later time points. This study established that in vitro MSC 
viability, expansion, and osteogenesis were not adversely affected by general anesthesia or short-
term euthanasia during tissue collection; however, both inter- and intra-donor variability 
influenced many of the outcomes measured, and the previous finding that equine adult BM-
MSCs are more osteogenic than ADI-MSCs was re-confirmed. 
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 The second experimental study (Chapter 4) characterized the RUNX2 and OSX 
regulatory axes of equine adult ADI- and BM-MSCs during osteogenesis to determine the effect 
of these genes on determining osteogenic differentiation capacity. The hypotheses were that 1) 
the relative osteogenic capacities of ADI- and BM-MSCs are consistent with resting and 
inducible RUNX2 and OSX expression levels, and 2) increasing OSX expression in ADI-MSCs 
improves their osteogenic capacity. Expression of RUNX2 and OSX under control and 
osteogenic conditions was evaluated at days 0, 2, 4, and 7 post-osteogenic induction. OSX, but 
not RUNX2, was significantly higher in resting BM- compared to ADI-MSC cultures. RUNX2 
up-regulation was similar in both cell types in response to osteogenic media, but only BM-MSCs 
significantly induced OSX by day 7. Next, OSX was over-expressed in ADI-MSCs using an 
adenovirus, and osteogenic responses were assessed at days 4 and 7 post-infection. OSX over-
expression did not consistently or significantly increase multi-cellular aggregation, Alizarin Red 
staining, ALP mRNA expression or enzymatic activity, or downstream mRNA expression of a 
panel of osteoprogenitor marker genes. This study established that differences in the RUNX2-
OSX response axes might partly influence the osteogenic capacities of BM- and ADI-MSCs, but 
over-expression of OSX was not sufficient to substantially improve osteogenesis in ADI-MSCs. 
 The third experimental study (Chapter 5) evaluated the comparative BMP signaling 
activities in equine adult ADI- and BM-MSCs. The hypotheses were that 1) osteogenic BMP 
ligand expression differs in ADI- and BM-MSCs, 2) BMP inhibition in BM-MSCs impairs 
osteogenesis, and 3) BMP addition to ADI-MSCs improves osteogenesis. MSCs were first 
evaluated for resting and osteogenesis-induction expression of BMP ligands -2, -4, -6 and -7. 
BM-MSCs had significantly higher BMP-2 and -4 transcript levels than ADI-MSCs. BM-MSCs 
were then subjected to BMP inhibition under control and osteogenic conditions by using the 
small molecule BMP receptor kinase inhibitors DMH-1 and K-02288 and the extra-cellular 
antagonist Noggin. OSX, but not RUNX2, mRNA expression was significantly and dose-
dependently down-regulated by BMP inhibition in both control and osteogenic conditions. BMP 
inhibition in BM-MSC cultures impaired multi-cellular aggregation, Alizarin Red staining, and 
ALP mRNA expression and enzymatic activity in a dose-dependent manner. Finally, 
recombinant human BMP-2 was supplemented to ADI-MSCs in both control and osteogenic 
conditions at 100 ng/ml, and samples were evaluated at days 2, 4, 7, and 10 post-osteogenic 
induction. BMP-2 supplementation significantly increased OSX expression and slightly 
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increased RUNX2 and ALP expression, while multi-cellular aggregation and Alizarin Red 
staining were improved over controls. This study first established that differences in baseline and 
osteogenesis-induced BMP signaling influence the osteogenic capacities of ADI- and BM-
MSCs, next demonstrated that endogenous BMP activity is required for BM-MSC osteogenesis, 
and finally showed that exogenous BMP supplementation in ADI-MSCs improves osteogenesis.  
Overall, the results of these studies indicate that MSCs collected from anesthetized and 
recently deceased donors show equivalent in vitro cell viability, proliferation, and osteogenic 
differentiation capacities as MSCs collected from awake but sedated donors. BM-MSCs show 
superior osteogenic differentiation to ADI-MSCs in part due to enhanced OSX induction in 
response to osteogenic cues and higher intrinsic BMP signaling in both resting and osteogenic 
conditions. Endogenous BMP activity is necessary for osteogenesis in BM-MSCs. Exogenous 
BMP supplementation, but not OSX over-expression by itself, was sufficient to improve the 
osteogenic capacity of ADI-MSCs. Therefore, the factors that influence the in vitro osteogenic 
capacity differences between equine adult BM- and ADI-MSCs are OSX expression and BMP 
signaling, while donor status during MSC collection does not impact in vitro cell behavior. 
The dissertation’s “Conclusion and Future Directions” (Chapter 6) first summarizes the 
results from each of the experimental study chapters, next provides an outline for follow-up 
studies, and finally describes the more global implications and recommended future research 
direction from the entire body of work. The studies globally re-confirmed that equine adult BM-
MSCs show superior osteogenic capacity to ADI-MSCs. The results of the first study indicate 
that MSCs from recently deceased donors can serve as a viable option for research and 
allogeneic stem cell use clinically. Donor variability significantly influenced outcomes, 
suggesting that donor inclusion criteria need to be established and MSC screening methods 
improved. The results of the second and third studies suggest that OSX induction and BMP 
signaling activity, but not RUNX2 levels, significantly influence the osteogenic capacity of 
different MSC populations. Enhancing BMP signaling had a more significant effect on 
improving osteogenesis in a less-osteogenic MSC population than OSX over-expression. In 
conclusion, MSCs from many sources can be utilized for bone repair and regenerative medicine, 
but there are certain modalities that are more effective at improving osteogenic capabilities based 






 Bone serves many diverse functions in the body. Although the cells on and within bone 
constitute a very small percentage of the tissue bulk (approximately 5%), surface osteoblasts and 
intra-osseous osteocytes are vital for ensuring appropriate matrix homeostasis and skeletal 
structural integrity. The development of bone during skeletogenesis and its regeneration during 
fracture repair utilize similar cellular and molecular processes, collectively termed ‘endochondral 
ossification’. Osteoblasts line the surface of bone, on the inner layers of the periosteum and 
endosteum. They are derived from mesenchymal stem cell (MSC) precursors through osteogenic 
differentiation and responsible for bone synthesis. MSC osteogenesis is regulated by the master 
transcription factors RUNX2 and Osterix (OSX), with interplay from several signaling pathways, 
most importantly TGF-β/BMP signaling. Downstream targets of RUNX2 and OSX include 
genes necessary for bone matrix deposition and mineralization. Although bone possesses the 
inherent ability to regenerate, repair failure can occur due to multiple factors, including ischemia, 
excessive instability, extensive gap formation, and infection. Bone regenerative therapies often 
utilize multi-modal approaches that can include bone grafting, growth factor delivery and other 
biologic therapeutics, biomaterials, gene therapy, and/or MSC implantation. MSCs are a 
promising therapeutic option due to their accessibility from several adult tissues such as bone 
marrow (BM) and adipose (ADI), high proliferative ability, and capacity for multi-lineage 
differentiation. This review first provides an overview of skeletal development, osteoblast 
differentiation, and bone regenerative medicine approaches. The remainder of the review focuses 
on MSC characteristics, cross-species BM- and ADI-MSC collection and isolation techniques, in 
vitro osteogenic differentiation models, and assays for measuring osteogenesis in vitro. 
Comparative osteogenic potentials of BM- and ADI-MSCs are discussed, with a focus on 
methods for improving osteogenesis based on the BMP-RUNX2-OSX regulatory axis, 
specifically BMP signaling enhancement and directed RUNX2 and OSX over-expression.  
 
Bone Structure & Function 
Bone is a dense, mineralized connective tissue that is formed and maintained by 
osteoblasts and osteocytes and resorbed by osteoclasts during remodeling and normal turnover. 
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Due to the structural rigidity of bone, its primary functions include support and protection of soft 
tissues and locomotion [reviewed in 1]. Bone is also vital for endocrine regulation of calcium 
and phosphorus, production of erythrocytes, platelets, and white blood cells within the bone 
marrow compartment, and metabolic processes such as fat storage and acid-base balance 
[reviewed in 2]. Bone contains three main cell types responsible for initial skeletogenesis, 
skeletal maintenance, and bone remodeling: osteoblasts, osteocytes, and osteoclasts. 
Bone is composed of approximately 50 – 70% bound minerals, 20 – 40% flexible matrix, 
5 – 10% water, and < 3% lipids [reviewed in 3]. Structurally, bone is classified as ‘cortical’ or 
‘trabecular’ [1 – 3]. Cortical or compact bone is dense and solid, and it surrounds bone marrow 
spaces. Trabecular or cancellous bone is less dense and is composed of a porous network of 
plates and rods. Trabecular bone is interspersed with bone marrow spaces, near the ends of long 
bones, and in the vertebrae. Both types of bone are composed of ‘osteons’, which consist of 
concentric layers or ‘lamellae’ of bone matrix interspersed with osteocytes and their canaliculi, 
surrounding a central Haversian canal [3].  
The organic phase of bone extracellular matrix consists of 85 – 90% elastic collagen 
fibers, predominantly collagen type I, and trace amounts of other collagens, also known as 
“ossein”. Collagen fibers are typically arranged into cylindrical lamellae to form lamellar bone; 
an arrangement that is mechanically superior to woven or fibrous bone that contain randomly-
organized collagen fibers [4]. The remaining matrix composition includes serum proteins, 
glycosaminoglycan-containing proteins, glycoproteins, and many other factors collectively 
known as “ground substance” [3]. The mineral content of bone is predominantly calcium 
hydroxyapatite, with small amounts of carbonate, magnesium, and acid phosphate [3]. Together, 
the mineral provides mechanical rigidity, allowing for load-bearing strength, while the organic 




The formation of bone during fetal development (skeletogenesis) occurs via two 
processes: intramembranous and endochondral ossification [reviewed in 5]. Intramembranous 
ossification involves direct mineralization of mesenchymal tissue, without an intermediate 
cartilaginous phase. Intramembranous ossification is responsible for formation of the flat bones 
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of the skull, jaw bones, and clavicles. In contrast, endochondral ossification involves the 
formation of bone from a pre-existing cartilage model, and it occurs during development of the 
remaining bones in the body. Endochondral ossification is also the process that drives most 
fracture repair, through callus maturation. 
 
Initiation & Patterning 
Skeletogenesis begins in the vertebrate embryo when multipotent mesenchymal stem 
cells (MSCs) originating from the ectoderm and mesoderm migrate and condense at specific 
locations in the embryonic body, and then commit to a skeletal fate [6]. The MSCs give rise to 
common osteo-chondro progenitor cells that are capable of differentiating along both 
chondroblastic and osteoblastic lineages. Specific fate commitment is largely determined by 
expression and activities of the master transcription factors SRY-like box 9 (SOX-9) and Runt-
related transcription factor 2 (RUNX2), respectively [7]. Morphogen and signaling networks, 
driven by bone morphogenetic proteins (BMPs), fibroblast growth factors (FGFs), retinoic acid, 
Sonic Hedgehog (Shh), and Wnt ligands, control the expression and activity of various 
patterning transcription factors [reviewed in 8].  
 
Cartilage Anlagen 
The initial skeletal framework is pre-figured through cartilaginous models, also referred 
to as ‘anlagen’. Anlaga form the template for both axial and appendicular skeletal elements. 
Initially, osteo-chondro progenitor cells aggregate, forming condensations, undergo 
chondroblastic differentiation, and begin producing cartilage extracellular matrix [5]. 
Chondrocyte proliferation and hypertrophy drive tissue elongation, which begins to shape the 
bone diaphysis and epiphyses. Terminally differentiated hypertrophic chondrocytes at the 
primary and secondary centers of ossification and, at later time points, the growth plates, secrete 
angiogenic factors and begin to express osteoblast markers, initiating the replacement of 
cartilage matrix with bone [5]. Several ligand-mediated pathways regulate chondrocyte 
maturation during endochondral ossification, including BMPs and transforming growth factor 
betas (TGF-β), growth hormone (GH), insulin-like growth factors (IGFs), thyroid hormone, 





The eventual replacement of the cartilage by bone at primary centers of ossification and, 
later, in growth plates occurs through endochondral ossification [reviewed in 5, 9]. Terminal 
chondrocytes undergo apoptosis, triggering chondro-osteoclastic resorption of the cartilaginous 
matrix, vascularization, and osteoblast migration to replace the cartilage with bone matrix [5]. 
Pre-hypertrophic chondrocytes secrete Indian hedgehog (Ihh), which induces osteoblast 
differentiation in the adjacent periosteum, leading to bone matrix formation [10]. Hypertrophic 
chondrocytes also secrete vascular endothelial growth factor (VEGF) to trigger blood vessel 
development in the forming bone [11]. Matrix metalloproteinases (MMPs) are secreted by 
terminal chondrocytes, degrading the surrounding cartilage to facilitate osseous substitution [12]. 
The close interactions between cartilage and bone cells during endochondral ossification result in 
the formation of primary ossification centers in the diaphyses and secondary ossification centers 
in the epiphyses and apophyses of long bones, and in developing cuboidal bones. 
 
Intramembranous Ossification 
Intramembranous ossification occurs when osteogenic progenitors form compact nodules 
within the developing skull bones [reviewed in 5, 13]. The cells become osteoblastic, without 
any chondrogenic intermediate, and produce an organic matrix that is mineralized from an 
ossification center in the center of each bone [13]. The skull bones remain connected by fibrous 
interfaces called “sutures” that serve as growth centers; they maintain a pool of undifferentiated, 
osteogenic cells that are recruited into ossification fronts until fusion of the sutures during post-




Osteoblasts are responsible for both intramembranous and endochondral ossification. 
They comprise 4 – 6% of the total bone cell population, reside along the surfaces of bone, and 
predominantly function as bone-forming cells [reviewed in 13]. They are derived from MSCs 
through osteogenic differentiation. Osteoblasts synthesize bone matrix by first secreting a non-
mineralized, organic matrix known as ‘osteoid’ that contains abundant collagen type I [reviewed 
in 5, 15]. As osteoblasts mature, they secrete bone-specific proteins, such as bone sialoprotein / 
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integrin-binding sialoprotein (BSP / IBSP), osteocalcin / bone gamma-carboxyglutamic acid-
containing protein (OSC / BGLAP), osteonectin / secreted protein acidic and rich in cysteine 
(OSN / SPARC), osteomodulin / osteoadherin proteoglycan (OSM / OSAD), osteopontin / 
secreted phosphoprotein 1 (OSP / SPP1), and other proteoglycans [reviewed in 14 – 16]. These 
osteogenic genes are often used to identify and monitor the osteogenic phenotype, 
experimentally. Matrix is then mineralized by osteoblasts, initially through a ‘vesicular phase’, 
which involves release of matrix vesicles containing calcium, enzymes that degrade 
proteoglycans, and alkaline phosphatase (ALP) to secrete phosphate ions from the vesicles. 
Ultimately, the calcium and phosphate from the osteoblast-derived vesicles form hydroxyapatite 
crystals, which are released during the ‘fibrillar phase’ of mineralization and integrate 
throughout the surrounding matrix [17]. The differentiation of osteoblasts and their functional 
processes are predominantly governed by the transcription factors RUNX2 and osterix (OSX), 
and multiple signaling pathways [reviewed in 15, 18]. 
 
RUNX2 
Runt-related transcription factor 2 (RUNX2), also known as core-binding factor subunit 
alpha-1 (Cbfa1) is considered a master osteogenic transcription factor as its inactivation in 
developmental murine models blocks osteoblast differentiation and results in a complete absence 
of mineralized bone [19, 20]. RUNX2 contains a ‘Runt domain’ near the N-terminal region that 
is responsible for binding DNA through an alpha subunit and hetero-dimerization with a non-
DNA binding core binding factor beta subunit [21]. RUNX2 targets downstream genes by 
binding to an osteoblast-specific element 2 (OSE2) in the promoter region of genes such as OSC, 
BSP, collagen type I α1 (COL1A1), and OSP [22]. While RUNX2 is necessary for osteogenesis, 
it is not sufficient for osteoblast differentiation from chondrocyte precursors [23].  
 
Osterix 
Osterix (OSX), also known as transcription factor Sp7, is also necessary for osteogenesis, 
as its deletion also blocks osteoblast differentiation and mineralized skeleton formation, similarly 
to RUNX2 [24]. OSX expression is dependent on and downstream of RUNX2: RUNX2-null 
mice do not express OSX, while OSX-null mice express RUNX2 with wild type spatial and 
distribution profiles [24]. The OSX promoter contains response elements for RUNX2 and several 
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other factors, such as DLX-5, SOX-9, and SP1 [reviewed in 26]. Downstream targets of OSX 
include COL1A1, BSP, OSC, OSN, OSP, and ALP [24, reviewed in 27]. OSX-null cells exhibit 
a pre-hypertrophic chondrocyte phenotype, suggesting that OSX is required to suppress 
chondrocytic differentiation of osteo-chondro progenitor cells and enable osteoblast 
differentiation of RUNX2-positive cells [24].  
 
Signaling Pathways  
Osteoblast differentiation is regulated by several signaling pathways, with the TGF-β / 
BMP networks arguably playing the most significant roles [reviewed in 28 – 29]. TGF-β ligand 
or receptor-deficient mice models show various defects ranging from reduced bone growth and 
mineralization or deformed bones to early embryonic lethality [28]. TGF-β autocrine and 
paracrine signaling is important in maintaining and expanding MSCs [30], and the sensitivity of 
osteoblasts to TGF-β’s mitogenic activity is directly correlated with developmental processes 
[reviewed in 31]. TGF-β signaling regulates osteoprogenitor proliferation, early differentiation, 
and osteoblast commitment through canonical Smad 2/3 networks, non-canonical MAPK 
pathways, and through interplay with Wnt, Hedgehog, Notch, FGF, and parathyroid hormone 
(PTH) signaling [28]. RUNX2 is a primary nuclear target of both canonical and non-canonical 
TGF-β signaling [28].  
BMPs are vital for both in vivo bone development and in vitro osteoblast differentiation 
[32].  BMPs were first discovered in 1965, following the observation that demineralized bone 
matrix implanted into muscular tissue induced ectopic bone formation [33]. BMP-deficient mice 
models often die too early in development to establish their skeletal phenotypes, and individual 
BMP ligands can compensate for each other or have antagonistic effects on bone formation 
[reviewed in 28, 32]. In vitro, recombinant BMP proteins applied to osteoblastic lineage cells 
enhance expression of bone-specific markers such as ALP, collagen type I, osteocalcin, and 
parathyroid hormone-related protein receptor (PTHrP) [32]. BMPs are able to stimulate 
osteoblast differentiation of several pluripotent cell lines while suppressing differentiation down 
myogenic [35] and chondrogenic [36] lineages. Similar to TGF-β signaling, BMPs regulate 
osteoblast differentiation through canonical Smad 1/5/8 networks, non-canonical MAPK 
pathways, and via interactions with Wnt, Notch, FGF, and hedgehog (Hh) signaling [28]. The 
primary nuclear targets of both canonical and non-canonical BMP signaling are RUNX2 and 
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OSX, with OSX also a secondary target through DLX-5 [28, 29]. The BMP regulatory axis will 
be discussed in further detail later in this review in the context of its control over RUNX2 and 
OSX activity, and utilizing BMPs to enhance osteogenesis.  
The canonical Wnt / β-catenin signaling pathway is important in the fate-determining 
decision of osteo-chondro progenitor cells to undergo osteogenesis instead of chondrogenesis 
[37]. Wnt signaling is involved in both endochondral and intramembranous ossification 
processes during development [38]. Over-expression of Wnt9a during later stages of cartilage 
development promotes endochondral bone formation, while targeted β-catenin removal in osteo-
chondro progenitor cells, which blocks Wnt signaling, significantly reduces embryonic bone 
formation in both the calvarium and long bones [37, 39]. The timing of Wnt signaling activity 
during endochondral ossification is crucial to regulate early chondrocyte differentiation and 
promote late stage osteoblast differentiation [37, 39].  
Hedgehog (Hh) family member signaling is involved in the regulation of skeletal 
development and homeostasis [reviewed in 37], with Ihh specifically required for osteoblast 
differentiation during endochondral ossification [10]. Ihh signaling was found to be upstream of 
Wnt / β-catenin during osteoblast differentiation in multiple mutant mice models. Ihh regulates 
the transition of pre-osteoblasts to RUNX2+ and OSX+ immature osteoblasts, while Wnt / β-
catenin functions in osteoblast maturation and is required after OSX expression [37].  
Fibroblast growth factor (FGF) signaling is involved in several processes during both 
intramembranous and endochondral ossification, with multiple FGF ligands showing specific 
spatiotemporal expression patterns during skeletogenesis [40]. FGF ligands -2, -4, and -6 were 
found to be inducers of osteoblast proliferation [41]. There are several gain- and loss-of-function 
FGF ligand and receptor mutations that result in skeletal diseases [reviewed in 40]. Many of the 
FGF receptor mutations appear to affect all cell types involved in skeletal development, 
including chondrocytes, osteoblasts, and osteoclasts. FGF signaling exerts its effects through 
Ras-MAP Kinase, protein kinase C (PKC), and PI3K / AKT networks [40], as well as cross-talk 
with previously mentioned signaling pathways.  
In addition to the significant cross-talk between the signaling pathways mentioned above, 
there are other important pathways involved in both positively and negatively regulating 
osteogenesis, including calcium (Ca
2+
) flux, insulin-like growth factor (IGF), platelet-derived 
growth factor (PDGF), and Notch signaling [reviewed in 42]. Many of these signaling networks 
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are common targets for therapeutic interventions in bone regenerative medicine, and BMP use 
will specifically be covered further in detail later in this review.  
 
Bone Regenerative Medicine Approaches 
Overview  
 Bone is one of the few tissues with the inherent ability to authentically regenerate; 
fracture healing mimics the cellular and molecular events of embryonic skeletogenesis [reviewed 
in 43]. Approximately 10% of fractures fail to repair adequately, often due to factors such as 
insufficient blood supply, infection, systemic disease, excessive bone loss, and inadequate 
stabilization [43]. Bone regenerative medicine often utilizes a multi-modal approach and can 
include techniques involving bone grafting materials, growth factors, blood- and bone marrow-
based therapeutics, biomaterial scaffolds, gene therapy, and cultured MSC transplantation. Each 
of these modalities have been extensively reviewed elsewhere [44 – 52], so the following 
sections will contain only a brief overview of bone grafting, growth factor use, gene therapy, and 
MSCs. The latter part of this review will discuss in vitro MSC techniques in more detail and then 
focus on BMP growth factor use and RUNX2 and OSX gene therapy approaches specifically. 
 
Bone Grafts  
In situations where fracture repair is likely to be compromised, the current “gold 
standard” approach is to use autogenous cancellous bone and/or bone marrow grafting to 
augment repair [45]. Bone grafts in humans are typically harvested from the iliac crest or, less 
commonly, the distal femur or proximal tibia [53]. Bone grafts contain osteogenic, 
osteoconductive, and osteoinductive properties [45]. Graft materials are osteogenic in that they 
contain osteoblasts, osteoconductive due to promoting capillary ingrowth and MSC migration, 
and osteoinductive in their promotion of mitogenesis of MSCs through release of BMPs and 
other osteogenic proteins [45, 53]. However, there are several limitations to autogenous bone 
grafting, including the limited availability of healthy donor tissue, loss of bone stock, and donor-
site morbidity issues [45, 53 – 54]. Allogeneic grafts provide an alternative, but screening of 
cadaveric donors, preparation, and storage of graft materials are highly complex and expensive 
processes, with the attendant risk of recipient rejection [45]. Ongoing research is focusing on 
alternative options to autografting, including xenografts and synthetic bone graft substitutes [44]. 
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Growth Factors  
Growth factor applications for bone repair capitalize on signaling proteins that are 
prevalent during normal bone development and remodeling processes, with the most common 
agents being BMPs [46]. BMPs 2 and 7 already have FDA-approved applications for spinal 
fusion and tibial non-union treatment [56, 57]. However, they may not be beneficial over control 
treatments in all types of fracture healing or non-union repairs [58], and their use carries risk of 
excessive or heterotopic bone formation [57 – 59]. Therefore, there is still ongoing research into 
the efficacy and strategic application (dose, carrier, etc.) of BMPs in various sites for bone 
healing [59]. The success of recombinant BMP use has expanded research into other growth 
factors, such as TGF-βs, FGFs, IGFs, VEGF, PDGF, and PTH, all of which show promise for the 
potential use in bone regeneration [reviewed in 60 – 65]. However, direct growth factor delivery 
to repair sites is often limited by insufficient local retention, high protein concentration 
requirements, and cost-inefficiency, thus warranting investigation into strategies to optimize their 
use by coupling with biodegradable carriers, MSCs, and/or biomaterials [66].  
 
Gene Therapy 
Gene transfer technologies have the potential to improve bone healing by delivering local 
and sustained expression of osteogenic genes to sites of repair. There are numerous strategies for 
modifying gene expression, such as viral vectors (retrovirus, lentivirus, adenovirus, adeno-
associated virus) and expression plasmids, with either ex or in vivo incorporation techniques 
[reviewed in 69 – 72]. Ex vivo approaches involve genetically engineering MSCs in vitro prior to 
implantation. In vivo strategies include direct injection of vectors, implantation of gene-activated 
matrices, or biomaterial-coupled delivery. There are numerous ‘osteogenic’ genes that have been 
investigated in this context, with the most common being BMPs, TGF-βs, and VEGF, due to 
their importance in stimulating osteogenesis and angiogenesis, or the osteogenic transcription 
factors RUNX2 and OSX [70, 71]. Clinical trials in animal models have been mostly promising, 
but the results have been inconsistent [70, 71]. For example, direct injection of BMP-2 or -6 
adenoviruses into defects in rats, rabbits, and horses resulted in improved defect healing, but in a 
commonly used sheep tibial osteotomy model, the results have been poor [70]. Traditional ex 
vivo approaches have been more successful in large animal models, including horses, goats, and 
pigs. The differing success between animal model studies can likely be attributed to 
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inconsistency in the gene delivery methods and doses, the type of bone defect used and extent of 
healing evaluated, and species-specific differences in osteogenic responses to a given gene 
target. There are numerous safety issues associated with gene delivery, such as possible DNA 
recombination with integrating retro- and lentiviruses, excessive gene over-expression, immune 
reactions, and tumor development [72]. A few human deaths in early clinical trials, which were 
mostly attributed to non-vector related factors, significantly impaired the continued advancement 
of the field [71]. Further research is needed to determine which gene(s), delivery technologies, 
and implantation approaches are most appropriate before human clinical trials can commence. 
Data is lacking in vital areas such as large animal studies using clinically-relevant bone defect 
models, pharmacological and toxicological safety trials, and optimizing which MSC source 
and/or scaffold material is most appropriate for ex vivo gene therapy approaches.   
 
Cell-Based Therapies 
Cell-based therapies seem to hold the most promise in replacing autogenous bone 
grafting, and extensive research has been performed investigating treatments ranging from direct 
injection of cells into bone defects to implanting MSC-seeded biomaterial scaffolds in bone 
repair sites [reviewed in 52]. MSCs can be isolated from a variety of adult tissues and fluids, and 
they are involved in multiple roles during fracture repair and bone regeneration [73 – 75]. MSCs 
contribute directly in these processes through osteogenic differentiation and indirectly through 
paracrine signaling and immune response modulation [74]. In addition to primary bone marrow 
aspirate-based cell therapies that do not require culture, there are multiple other cell-based 
therapy modalities that utilize in vitro expansion and selection, and implantation with and 
without biomaterial matrices [75]. Cell culture techniques allow for expansion and screening of 
the MSC population prior to in vivo use, but can be both time- and cost-consuming, and in the 
context of human clinical applications, create substantial ‘chain of custody’ requirements that 
add cost and complexity to the procedures. There has been a multitude of studies and clinical 
trials that utilized cell-based therapies for various bone healing or regeneration purposes with 
generally successful outcomes [reviewed in 74, 75]. The use of allogeneic stem cells could prove 
beneficial in patients with non-unions that lack sufficient or healthy osteoprogenitor cells 
themselves [74], although safety and regulatory requirements have yet to be established for 
allogeneic stem cell banking [76]. Limitations associated with cell-based therapy alone include 
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inadequate delivery or survival of appropriate numbers of cells at the site of repair, infection 
risks, and donor morbidity associated with tissue harvesting [77].  
The remainder of this review will focus on MSC characteristics, comparative in vitro 
techniques across species, in vitro osteogenesis approaches, and methods for improving 
osteogenesis with a focus on the BMP, RUNX2, and OSX regulatory axes. 
 
Mesenchymal Stem Cells 
Characteristics  
MSCs are self-renewing and multi-potent cells, although their exact definition and roles 
vary within the literature [78]. MSCs were originally identified by their in vitro characteristics, 
which include their ability to adhere to plastic culture substrates, capacity for substantial clonal 
expansion, and differentiation ability along several mesenchymal tissue lineages [79, reviewed in 
80]. Adherence to cell culture plastic was a criterion originally established for bone marrow-
derived MSCs as it excluded hematopoietic lineage cells also found in marrow aspirates [79]. 
Clonal expansion eliminates terminally-differentiated cell types, allowing for a population of 
predominantly stem cells to develop over time, through continued cell proliferation [80]. 
However, MSCs are prone to senescence, which is associated with a loss of multi-potency [81]. 
Multi-potency of MSCs is typically tested as a tri-lineage capacity, since in vitro adipogenic, 
chondrogenic, and osteogenic differentiation protocols and outcome assessments are well-
established [80]. An additional criterion for defining MSCs, based on cell surface marker 
profiling, has been proposed more recently and includes identifying positive and negative 
markers [82]. Surface markers are well-characterized in human MSC populations [reviewed in 
83], but surface marker criteria in other species is highly variable and non-specific [84].  
 
Sources & Uses 
MSCs were initially isolated from bone marrow [79], but numerous other adult tissues 
and fluids contain MSC populations, including but not limited to adipose tissue, umbilical cord 
blood and Wharton’s jelly, periosteum, muscle, synovium, tendon, and circulating blood [78, 80, 
82, 85, 86].  Stem cells reside in specialized local environments known as “niches” within their 
tissue of origin, which provide support and appropriate stimuli to maintain “stemness” in MSC 
populations. Stem cell niches are generally located close to vasculature to allow rapid 
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mobilization of MSCs in response to local and systemic signals. Self-evidently, accessing niches 
is crucial to the efficient harvesting of MSCs, regardless of the specific source [86]. 
The widespread use of MSCs in tissue regeneration studies is a consequence of several 
stem cell characteristics, including homing to sites of inflammation, direct contributions to 
healing processes, their ability to differentiate into various cell types, local effects on tissues and 
other cells, and anti-inflammatory and immuno-modulatory properties [reviewed in 87, 88]. 
These beneficial activities have been documented in preclinical animal model studies [reviewed 
in 87], and human clinical trials using MSCs for multiple target conditions are extensive and 
ongoing [reviewed in 88].  
 
MSC Collection & Isolation Techniques 
Overview 
The following sections will focus on the two most readily available sources of MSCs in 
most species, bone marrow (BM) and adipose tissue (ADI). The variability in bone marrow and 
adipose tissue collection approaches complicates cross-species study comparisons due to 
differences in donor status during collection and potential site-specific variation in the bone 
marrow and adipose MSC niches. Sample processing techniques are relatively similar across 
species with regard to isolation of MSCs from bone marrow aspirates and adipose tissue 
samples. However, there does not appear to be a consensus as to the best type of cell culture 
media or additives to use, and there are subtle differences in recommended protocols for 
culturing and expanding MSCs both across and within species.  
 
Bone Marrow Collection & Isolation 
Bone marrow aspiration from live patients requires aseptic site preparation and use of a 
Jamshidi bone biopsy needle to penetrate the medullary cavity of the bone being harvested from. 
Common sites for bone marrow aspiration in humans are the iliac crest, sternum, and femoral 
head, and the procedure is commonly performed while the donor is under anesthesia [89, 90]. In 
animal models, the source and method of harvest is highly variable. In rodents, bone marrow is 
collected from recently euthanized animals by flushing the femoral marrow cavity [91]. In dogs, 
bone marrow can be collected from the wing of the ilium, proximal medial tibia, and proximal 
humerus, typically under general anesthesia [92]. Cats usually have bone marrow aspiration 
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performed from the proximal humerus [93]. In horses, bone marrow is routinely harvested from 
the sternum or iliac crest under standing sedation and restraint [94]. In many food / production 
animal species, it is common to perform MSC research on bone marrow harvested from abattoir-
derived samples, with considerable variability in the time lapse between death and stem cell 
collection [95]. There are numerous reported uses of bone marrow-derived MSCs for treating a 
variety of clinical conditions in veterinary medicine [96].  
Bone marrow aspirates contain a relatively low density of MSCs (< 0.01% of the total 
cell population), so there are several techniques that involve varying degrees of “concentrating” 
the sample prior to plating [94]. Classic techniques involve transferring the entire aspirate 
directly into tissue culture flasks or first centrifuging the sample to condense cellular contents 
and remove liquid components [91, 94]. These techniques rely on the assumption that only 
MSCs will selectively adhere to the culture vessel plastic, thus eliminating non-MSC cells. 
Additionally, aspirates can be treated with red blood cell-lysing agents, such as 0.8% ammonium 
chloride. Bone marrow aspirate can be placed in a density gradient solution, such as Ficoll or 
Percoll, to separate the mononuclear cell fraction from other blood and bone marrow components 
[90, 94]. Depending on the processing method, it may be possible to count mononuclear cells 
prior to plating, although this does not provide a direct indication of stem cell numbers. 
 
Adipose Tissue Collection 
 Adipose tissue is usually isolated from subcutaneous fat stores, thus necessitating 
removal of surrounding connective tissue and parenchyma. For this reason, adipose tissue 
collection often involves minor surgical procedures [89, 92, 94]. In humans, the most common 
collection technique for adipose tissue is lipo-aspiration [97]. In rodents, adipose tissue is 
harvested from recently euthanized animals and typically taken from intra-abdominal or 
epididymal / testicular locations [98]. In dogs, common collection sites for adipose tissue are the 
falciform ligament or omental tissue, which have been shown to be superior sources of MSCs 
over subcutaneous fat stores due to higher cell yields regardless of body condition, but require 
general anesthesia and invasive surgical approaches [99]. Cats can have adipose tissue harvested 
under sedation via punch biopsy of the ventral abdomen due to abundant fat stores located caudal 
to the umbilicus [93]. In horses, adipose tissue is typically collected from subcutaneous stores 
adjacent to the tail head, which is performed on sedated animals using local anesthetic [94]. 
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There are many reported uses of adipose-derived MSCs in veterinary medicine for orthopedic 
and non-orthopedic conditions [100].  
Adipose tissue samples also contain a relatively low density of MSCs compared to 
adipocytes, fibroblasts, and other parenchymal cells within the tissue. Therefore, MSCs must be 
liberated from the tissue by various digestion and agitation techniques. Samples are typically 
minced into smaller pieces, separated into phases, and digested using a 0.1% collagenase 
solution in PBS or culture media [89, 94, 98]. Agitation can be performed by vortexing [98] or 
incubation at 37
o
C in an orbital shaker [89, 94] to improve collagenase digestion efficiency. 
Digested adipose tissue can additionally be filtered through 70 and 40 μm filters to remove 
poorly digested debris. The suspension is centrifuged to pellet the vascular-stromal fraction 
containing the MSCs, which is then washed several times prior to counting, to exclude the more 
buoyant adipocytes [89]. Some sources recommend different initial cell seeding densities based 
on the source of the adipose tissue, but they generally range from 1 – 10,000 cells/cm
2
 [89].  
 
MSC Culture 
 MSCs are typically cultured and expanded in “growth media” with the addition of 10 – 
20% fetal bovine serum (FBS).  The most commonly used base media formulations are 
variations of Eagle’s Minimal Essential Medium (MEM), such as α-MEM and Dulbecco’s MEM 
(DMEM) [89, 91, 94], although DMEM-Ham’s F12 is also occasionally used [89, 94, 98]. 
Antibiotics are routinely added, most commonly penicillin (100 U/ml) and streptomycin (100 
μg/ml) [89]. Antifungals such as amphotericin B (25 μg/ml) are sometimes also included [98]. A 
comparative study using human bone marrow MSCs found that α-MEM + 10% FBS + Glutamax 
or L-glutamine resulted in the fastest in vitro expansion while preserving multi-potency [101]. 
The study also found that lower initial cell seeding densities of 1,000 cells/cm
2
 resulted in higher 
numbers of passage 0 (P0) adherent cells and greater MSC-enrichment than with densities higher 
than 25,000 cells/cm
2
 [101]. Collectively, it appears that there is no steadfast rule regarding 
growth media formulations or seeding densities for MSCs, suggesting that they respond 
reasonably consistently across species during in vitro expansion. 
MSCs will adhere within the first 72 hours of culture [79]. Within 1 – 2 weeks, MSCs 
will appear in clusters as spindle-shaped, fibroblast-like cells, reflective of clonogenic expansion 
[89]. Since such a small proportion of adherent cells are ultimately MSCs, homogeneity of the 
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culture can only be achieved after prolonged culture of at least 2 – 3 weeks and up to passages 3 
and 4 [79], to enrich for the persistently proliferative stem cell sub-population. Culture medium 
is typically changed 2 – 3 times per week, with some sources recommending the removal of only 
40 – 50% of the existing volume to preserve soluble factors released by the cells [89]. Cell 
contact inhibition occurs when culture reach near confluence (70 – 80%), upon which 
detachment via 0.05% trypsin-EDTA is recommended [101]. MSCs have higher sensitivity to 
trypsin than other adherent cell types [102]; thus, it is recommended to limit trypsinization to 5 – 
7 minutes at 37
o





has been shown to improve their proliferation rate and preferentially enhance their 
expansion [89, 102]. However, care must be taken not to over-passage MSC cultures as there is a 
clear link between increased passage number or time in culture and senescence [103, 104]. It has 
been shown that bone marrow MSCs reach senescence faster than adipose- and umbilical cord- 
derived MSCs [104].  
MSCs can be assessed for “stemness” characteristics, such as self-renewal and 
clonogenicity, by performing a colony-forming unit (CFU) assay or evaluating cluster of 
differentiation (CD) cell surface markers. CFU assays are carried out by seeding very low 
density of cells (such as 18 cells/cm
2
), and then observing the culture regularly to identify 
individual colonies of cells originating from a single parent cell. The number of colonies present 
reflects the self-renewal potential of the initial cell population [105]. CD markers on the cell 
surface can be evaluated through immunocytochemistry or flow cytometry [94]. Human MSCs 
should express CD73, CD90, and CD105, but they should not express CD11b, CD14, CD19, 
CD34, CD45, CD79, and major histocompatibility complex II (MHC-II) [89]. Other markers of 
human MSCs include CD29, CD44, CD106, and CD166 [79]. The International Society for 
Cellular Therapy defines the surface markers for human MSCs, but there is not a consensus 
regarding markers for other species. This is partially due to a lack of species-specific antibodies 
and lack of cross-reactivity with available antibodies for human targets [94]. MSCs are also 
routinely evaluated for multi-lineage differentiation, typically for tri-lineage adipogenic, 






In Vitro Osteogenic Differentiation 
Osteogenic Induction Media 
 In vitro osteogenic differentiation is induced in monolayer cultures of MSCs, typically 
passage 3 or 4 due to presumed homogeneity of cells and a more ‘pure’ MSC population. 
Growth media, as previously described, is supplemented with ascorbic acid, β-glycerophosphate, 
and dexamethasone to produce osteogenic “induction” media (OIM) [80, 89]. Additional 
additives to OIM sometimes include 1,25-Dihydroxyvitamin D3 and recombinant BMP-2 [106]; 
these are shown to have added benefit in improving osteogenic outcomes over OIM alone in less 
osteogenic progenitor cell populations [107].  At least three weeks of continuous treatment with 
OIM is required for complete osteogenic differentiation, but clear indications of phenotypic 
commitment are usually evident by day 7 in responsive cultures [108]. Ascorbic acid, β-
glycerophosphate, and dexamethasone are necessary over the entire differentiation process 
[reviewed in 109]. It has also been shown that allowing cultures to concentrate their soluble 
products in the media by performing partial media replacement improves osteogenic outcomes, 
likely through retention of autocrine and paracrine signaling [110]. The following section will 
elaborate on the roles of each additive in further detail. 
 
Ascorbic Acid 
Ascorbic acid (Vitamin C) is used in several formulations, most commonly L-ascorbic 
acid, L-ascorbic acid-2-phosphate, and L-ascorbic acid phosphate magnesium salt n-hydrate, 
with the phosphate analogs being more stable in culture conditions [109]. Its activity is primarily 
in collagen biosynthesis as it serves as an essential cofactor for prolyl lysil hydrolase, but it also 
possesses antioxidant functions [111]. Production of collagen in the extracellular matrix is 
necessary for osteoblast differentiation, as it results in integrin-mediated activation of the MAPK 
signaling pathway, with downstream targets such as RUNX2 being upregulated [112]. The 
optimal concentration of ascorbic acid-2-phosphate for osteogenic differentiation of human bone 
marrow MSCs was found to be 0.05 mM [110], yet up to 0.3 mM is used in some species [94]. 
 
β-glycerophosphate 
β-glycerophosphate is typically used as disodium salt hydrate formulations. It primarily 
serves as a source of phosphate for hydroxyapatite deposition during bone formation, but it may 
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also influence intracellular signaling molecules through liberation of inorganic phosphate [109]. 
Phosphate activates MAPK/ERK signaling pathways that induce downstream osteogenic genes 
such as OSP and BMP-2 [109]. BMP-2 expression is also increased by phosphate through the c-
AMP/PKA pathway [109]. The optimal concentration of β-glycerophosphate for osteogenic 
differentiation of human bone marrow MSCs was determined to be 10 mM [110], but 
concentrations greater than 2 mM can result in non-apatitic or “dystrophic” mineralization as a 
product of cell death in populations lacking osteogenic differentiation capacity [113].  
 
Dexamethasone 
Dexamethasone is a synthetic glucocorticoid that can preferentially induce MSCs toward 
adipogenic, chondrogenic, and osteogenic lineages depending on the concentration and other 
factors present in the media formulation [106]. Its exact mechanisms of action during 
differentiation aren’t well defined, but it enhances the responsiveness of MSCs to other 
differentiation stimuli since it does not define any specific lineages by itself. Dexamethasone 
directly induces RUNX2 expression and activity through the Wnt/β-catenin signaling pathway 
[114], activating TAZ [115], and de-phosphorylating RUNX2 through MAPK phosphatase 
(MKP-1) [116]. Dexamethasone induces apoptosis in MSC populations that have poor intrinsic 
differentiation capacity [117], prevents apoptosis in confluent cultures [108], and promotes MSC 
proliferation [118]. The optimal concentration of dexamethasone for osteogenic differentiation of 
human bone marrow MSCs was determined to be 100 nM [110], but concentrations as low as 10 
nM are commonly used with similar efficacy [119].  
 
Assays for In Vitro Osteogenesis 
Overview 
There are numerous assays for in vitro osteogenesis that are routinely used to assess the 
quality and degree of differentiation. These include observing and counting multi-cellular 
aggregate formations over time, determining expression profiles of osteoblast-specific gene 
transcripts, measuring alkaline phosphatase enzymatic activity through staining and colorimetric 
assays, staining for mineralized matrix with Alizarin Red or Von Kossa dyes, and, in late stage 
cultures, quantifying calcium deposition in the matrix. The following sections describe the 




In the early stages of in vitro osteogenesis, permissive cell monolayers initially adopt a 
‘herringbone’ alignment, before coalescing into dense, multi-cellular aggregates. Aggregate 
counting is not a commonly used osteogenic differentiation outcome measure, but it serves as a 
straightforward and self-evident quantitative assay for early cellular responses to osteogenic 
stimuli [120]. Aggregation is not specific for osteogenic differentiation as it also occurs during 
adipogenic differentiation, and it is often considered necessary for chondrogenic differentiation 
since cultures are typically pelleted or grown in micro-masses [80]. The concept of counting 
aggregates over time to assess osteogenic capability is based on the observation that cultures 
showing little or no aggregation also do not tend to have other positive osteogenic assay 
outcomes [120]. As previously reviewed, MSC migration in vivo is necessary for multiple 
processes during development and bone repair/remodeling, and it is responsive to many systemic 
cytokines and local paracrine cues. Cell-cell contact is essential for osteogenic differentiation, 
due in part to specific interactions mediated by cadherin-11 [121] and gap junctions [122], and 
other contact-dependent signaling pathways [108]. Although counting cellular aggregation 
during in vitro osteogenesis is an easy way to monitor early differentiation, it is neither sensitive 
nor specific for osteogenesis as cellular aggregation is influenced by multiple factors other than 
differentiation cues alone, such as chemotaxis in response to paracrine signaling and direct cell 
contact-mediated signaling [122, 123]. 
 
Osteogenic Gene Expression 
Gene expression profiling is one of the more specific assays for osteogenesis. There are 
multiple genes that are routinely evaluated, specifically the master transcription factors RUNX2 
and OSX, their upstream regulators (transcription factors DLX-5 and MSX-2, plus several 
additional signaling pathway effectors), and their common downstream targets. A large-scale 
study evaluated multiple sources of literature and bioinformatics databases to classify the major 
genes involved in osteogenesis into four categories: cell migration, skeletal development, 
calcium ion binding, and ossification. The “Leader” genes involved in ossification were found to 
be the common osteoblast markers RUNX2, BMP-2, and OSN/SPARC, with “class B” genes 
including OSP/SPP1, OSM, BMP-4, MSX-2, and several others involved in secondary processes 
[125]. A microarray-based study found that ALP, BSP/IBSP, OSP/SPP1, OSC/BGLAP, and 
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COL1A1 were all important markers of osteogenesis and reflected osteoprogenitor commitment 
and osteoblast maturation [126]. It is well-established that RUNX2 is not osteoblast-specific but 
instead serves as markers for osteo-chondro progenitors; therefore, it is most appropriately used 
in evaluation of pre- or immature osteoblasts, especially since RUNX2 expression inhibits later 
stage osteoblast maturation [127]. OSX expression peaks in pre-osteoblasts and remains high 
through most of osteoblast differentiation [reviewed in 128], but it too can also inhibit late stage 
osteoblast maturation [129]. ALP and COL1A1 peak in pre-osteoblasts and remain high 
throughout differentiation [130]. OSP precedes expression of BSP and OSN, while OSC is 
expressed in fully differentiated osteoblasts [130]. In summary, there are multiple marker genes 
for osteoblast differentiation, and it is important to be aware of their roles and temporal 
expression profiles when evaluating osteogenesis in a cell population, regardless of the 
methodology used.  
  
Alkaline Phosphatase 
ALP activity is commonly evaluated through monolayer staining and/or bioactivity 
assays. Histochemical staining for ALP activity typically relies on phosphatase enzymatic 
activity to dephosphorylate molecules under alkaline conditions, which is monitored through the 
generation of a colorimetric dye. A common substrate is napthol AS-BI phosphate, with color 
development produced by fast red violet LB or fast blue BB salt compounds. Fluorescent and 
immunostaining methods are able to identify ALP activity, but these do not allow for easy 
quantification. ALP activity assays utilize p-nitrophenyl phosphate as a substrate that is 
hydrolyzed to produce p-nitrophenol, resulting in a yellow end product measurable at an 
absorbance of 405 nm wavelength [131]. ALP is a downstream target gene of both RUNX2 and 
OSX, and its expression is also induced by dexamethasone, BMP-2, and vitamin D3 [132]. ALP 
activity increases during in vitro osteogenesis, with low levels apparent by 1 week and a 2 – 6 
fold increase at later time points [132]; however, its expression decreases when mineralization is 
advanced [130]. There is often a poor correlation between ALP gene expression and enzymatic 
activity levels in stem cell osteogenesis studies. One study found that levels of ALP activity are 
not proportional to observed mineralization levels, which is considered the ultimate endpoint of 
in vitro osteogenesis [132]. ALP is necessary, but not sufficient, to produce mineralized matrix, 
as some bone marrow MSC cultures in growth media can exhibit high ALP levels but show a 
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delay in mineralization compared to dexamethasone-treated cultures [133]. Other bone marrow 
MSC cultures produce high levels of ALP without ever mineralizing [134]. Therefore, the 
correlation between ALP activity and mineralization is dependent on the source and quality of 




Alizarin Red staining is commonly used as a means to visualize mineralization as an 
endpoint of in vitro osteogenesis. Alizarin Red is an anthraquinone derivative that forms a 
complex with calcium, manganese, barium, strontium, and iron ions through chelation [135]. In 
MSC cultures, calcium ions are the only substrates present at a sufficient levels for detection 
with staining.  Alizarin Red stain can be extracted from fixed cells using a protocol involving 
acetic acid and ammonium hydroxide, which is then quantified by absorbance at 405 nm 
wavelength [136]. A positive stain results in calcium salts appearing deep orange or red under 
plain or compensated polarized light microscopy. The main benefit of Alizarin Red staining is 
that it is a simple and fast protocol that works on fixed tissue, fluid, and cell culture samples. 
However, there is a high rate of false positives [137, 138], and quantitative measurements of 
stain uptake are not particularly sensitive as clear increases in Alizarin Red binding are generally 
only detectable in very late stages (14 – 21 days) of osteogenic cultures. There is also a high 
amount of background and sequestered stain sometimes present in cellular aggregates, making 
subjective interpretation of the “positivity” of the staining results difficult. Alizarin Red staining 
can also be strongly “positive” in cultures undergoing cell death due to release of intracellular 
calcium ions that can be absorbed into the surrounding matrix.  
 
Von Kossa 
Von Kossa staining also detects matrix mineralization by binding to phosphate in the 
matrix. The staining reaction relies on silver nitrate reacting with phosphate ions in an acidic 
environment to produce a precipitate [139]. Photochemical degradation of the silver phosphate 
precipitate results in a black, metallic silver product. While the stain does not directly detect 
calcium, the silver essentially replaces the calcium in the calcium phosphate complex. There 
have been several modifications of the original protocol to better optimize its use [140, 141]. 
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Although von Kossa staining has been increasingly used in osteogenic cultures to detect 
“calcium” in mineralized matrix, it has been found to be insufficient to confirm that 
mineralization in vitro actually reflects in vivo bone matrix-forming capacity [113]. Bonewald et 
al showed that cultured cells failed to form hydroxyapatite mineral even after 30 days in culture 
using Fourier-transform infrared spectroscopy (FT-IR) and electron microscopy (EM) analyses, 
despite being strongly positive for von Kossa staining. Similar to Alizarin Red, there is a high 
likelihood of obtaining false positive results [142].  
 
Calcium Quantification 
Matrix calcium quantification can be performed using o-cresolphthalein complexone, 
which binds to calcium ions to form a chromophore in alkaline medium [143]. The compound 8-
hydroxyquinoline is then added to reduce any interference by magnesium, and the absorbance is 
measured at 570 nm wavelength [135]. Other methods of quantifying calcium deposition include 
fluorescent dyes, such as calcein, coelenterazine, dehydrocalcein fluo-3, fura-2, indo-1, and 
rhod-2 [144], or colorimetric kit assays [145]. The major concern with calcium quantification 
assays is that they are not specific for the type of calcium detected, and the quantification of 
calcium content in a cell layer does not allow for accurate evaluation of mineralization [145]. As 
with mineral staining procedures, false positives can exist from things such as apoptotic bodies 
producing non-apatitic calcification [146]. The determination of the ‘calcium to phosphate’ ratio 
is more important than calcium quantification alone, since human bone has a ratio of 1.63 [147]. 
Analysis of the matrix structure through advanced imaging methods, such as x-ray diffraction, 
FTIR, and EM, is necessary to truly confirm hydroxyapatite secretion and exclude other calcium 
phosphate-based compounds in the matrix [148]. 
 
Improving Osteogenic Differentiation of MSCs 
Comparative Osteogenic Potentials 
Bone marrow MSCs (BM-MSCs) were the first source of MSCs derived from human 
samples shown to possess multi-lineage differentiation potential [79], yet their cell yield, long 
expansion time, and earlier senescence risk are disadvantageous compared to MSCs from other 
sources, such as adipose tissue (ADI-MSCs) [149]. However, there is extensive literature 
documenting the superior osteogenic capabilities in BM-MSCs compared to other donor-
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matched progenitor populations [149 – 156]. This is hardly surprising, given the location of BM-
MSCs within the actively remodeling osseous environment of the medullary cavity. ADI-MSCs 
showed delayed collagen type I deposition, ALP activity, and osteogenic gene and protein 
expression compared to BM-MSCs [151].  In another study, BM-MSCs showed superior ALP 
activity and von Kossa staining compared to ADI-MSCs collected from non-donor matched 
samples in older patients [152]. BM-MSCs have also shown accelerated and/or superior 
osteogenic differentiation capabilities compared to ADI-MSCs in rats [153], pigs [154], and 
horses [155, 156], while results in dogs have been mixed [57, 158]. In animal model studies, the 
results are largely inconclusive regarding which cell source has superior osteogenic potential in 
vivo [150]. Excluding donor-specific differences in cell proliferation and differentiation 
capabilities, ADI- MSCs on their own likely cannot replace BM- MSCs for osteogenic purposes. 
Therefore, several approaches can be employed to improve the osteogenic capacity of MSCs 
from less osteogenic sources by capitalizing on normal osteogenesis regulatory processes. 
 
The BMP-RUNX2-OSX Regulatory Axis 
 The critical importance of BMP signaling and activities of the master osteogenic 
transcription factors RUNX2 and OSX make them ideal targets for improving bone formation 
both in vitro and in vivo. Both canonical and non-canonical BMP signaling activities are 
necessary for bone formation [28]. Canonical BMP signaling involves BMP ligand binding to 
receptor type II and type I, which results in formation of a heteromeric complex of 
serine/threonine kinase receptors. Activated type I receptors initiate intracellular signaling 
through phosphorylation of Smad proteins (1/5/8). Activated Smads form a complex with Smad-
4, translocate into the nucleus, and bind to Smad-Binding Elements (SBE) on target genes to 
direct transcriptional responses. Two direct transcriptional targets of canonical BMP signaling in 
osteogenesis are RUNX2 and DLX-5 [28]. In contrast, non-canonical BMP signaling is not 
Smad-dependent, but involves transforming growth factor-beta-activated kinase-1 (TAK1), a 
component of a MAP kinase pathway [159]. The TAK1/MAPK pathway mediates 
phosphorylation of RUNX2, increasing the association with its coactivator, CREB-binding 
protein, and regulating expression of downstream osteoblast-specific genes [160]. The ligands 
BMP-2, -4, -5, -6, and -7 all have strong osteogenic capabilities, and BMP-2 especially has been 
found to be necessary and sufficient for osteo-chondral differentiation of MSCs [161]. 
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 BMP autocrine signaling is required for RUNX2-dependent osteogenesis, as the 
pathways work synergistically to stimulate osteoblast gene expression [162, 163]. In addition to 
being a direct transcriptional target of BMP signaling, RUNX2 expression is also indirectly 
induced through DLX-5 [164]. RUNX2 acts upstream of the other master regulator of 
osteogenesis, OSX, [24], but OSX induction by BMP signaling is not mandatorily dependent on 
RUNX2 [165 – 167 ]. RUNX2-independent induction of OSX by BMPs is mediated through 
DLX-5 and MSX-2, as blocking of either factor results in complete absence of BMP-induced 
OSX expression [165 – 167]. In RUNX2-deficient cells, OSX was able to regulate expression of 
genes not controlled by RUNX2, suggesting that at least some of their osteogenic activities and 
target genes are distinct [167]. Another OSX regulatory factor, protein kinase B (PKB / AKT), 
phosphorylates OSX and DLX-5, which results in increased protein stability and osteogenic 
transcriptional activity [168, 169]. In summary, there is a complex interplay between BMP 
signaling, RUNX2, and OSX regulation during osteogenesis. While all three factors have been 
found to be essential for complete osteogenesis, it appears that BMP signaling, being the furthest 
upstream, influences the osteogenic capabilities of a cell most comprehensively and therefore is 
an ideal target for therapeutic approaches. 
 
BMP Signaling Enhancement 
 Given the importance of BMP signaling in both bone formation and repair [170], a 
common approach for improving osteogenic capacity of cells, both in vitro and in vivo, is 
potentiating the BMP signaling cascade. Two widely used methods to accomplish this include 
supplementing cells with exogenous recombinant BMP ligand or increasing BMP expression 
levels through gene delivery [171]. There are other strategies that help activate and maintain the 
BMP signaling response, such as neutralizing extracellular BMP antagonists, inactivating 
endogenous inhibitors, and regulating Smad protein modifications with small molecule inhibitors 
[172]. The Food and Drug Administration (FDA) has approved two recombinant human BMP 
products for clinical applications: InFuse/BMP-2 (Medtronic) and OP-1/BMP-7 (Stryker 
Biotech). They were initially approved for spinal fusions and fracture non-unions but have since 
been used extensively off-label for many orthopedic procedures [173, 174]. However, their use 
in spinal fusion procedures has been associated with complication rates of 10 – 50%, depending 
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on the surgical approach, which includes adverse events such as ectopic bone formation, 
osteolysis, implant displacement, and infection [175].  
 Exogenous BMP administration in vitro variably improves osteogenic differentiation 
capabilities of ADI-MSCs, depending on the specific ligand, the concentration used, 
differentiation media additives, and administration time point [175]. Very high concentrations of 
BMP-2 (300 – 500 ng/ml) can induce osteogenic differentiation without additional media 
additives in ADI-MSCs, yet mid-range doses (5 – 200 ng/ml) require ascorbic acid and β-
glycerophosphate in the media [176]. The optimal effect of BMP-2 in ADI-MSC in vitro 
osteogenesis was seen at a dose of 100 ng/ml [176]. Gene technology approaches to increasing 
BMP signaling attempt to avoid the costs and side effects associated with recombinant BMP use 
[177]. Common methods include viral or non-viral vector expression of BMP ligands and other 
key signaling components, and gene knockdown of BMP antagonists. There have been many in 
vivo and ex vivo gene therapy studies performed in animal models utilizing various BMP ligand 
over-expression modalities, and the results are mostly favorable in their ability to improve bone 
regeneration [reviewed in 178 – 179]. However, the issue regarding the cost-effectiveness of 
recombinant BMP ligand application under clinical conditions is far less certain. Ongoing 
research is focusing on temporally and spatially regulated gene expression systems to control the 
timing, localization, and extended delivery of BMP activity, which should further improve safety 
and efficacy over current recombinant protein-based therapies [180].  
 
Direct RUNX2 & OSX Expression 
 Both RUNX2 and OSX are necessary for osteoblast differentiation [19, 20, 24]. MSCs 
are directed toward osteoblast progenitor differentiation initially by RUNX2 and Ihh, while OSX 
and canonical Wnt signaling direct RUNX2-positive osteoblast progenitors into an immature 
osteoblastic phenotype [181]. The roles of RUNX2 and OSX in the maturation of osteoblasts are 
less well-established, but both can inhibit late osteoblast differentiation and transformation of 
mature osteoblasts to osteocytes [127, 129, 181]. Therefore, sustained over-expression of 
RUNX2 and OSX may not be beneficial for stimulating complete osteogenesis, and inducible or 
transient expression strategies are likely to be more effective approaches [182]. The following 
summarizes studies that have addressed RUNX2 and OSX over-expression, alone or in 
combination with other factors. 
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 RUNX2 adenoviral-directed over-expression in MSCs was found to enhance osteogenic 
differentiation and upregulate osteoblast-specific in vitro and improve healing in vivo in murine 
calvarial [183] and femoral [184] critical-size defects. RUNX2 adenovirus injected directly into 
femoral bone marrow induced osteogenesis, suggesting that direct approaches could be 
advantageous over ex vivo gene therapy protocols [185]. Retroviral-directed over-expression of 
both RUNX2 and mitogen-activated protein kinase (MAPK / MKP-1) effectively trans-
differentiated pre-adipocytes into fully differentiated osteoblasts [186]. Compared to BMP-2 
over-expression, transplanted fibroblasts expressing RUNX2 were not as effective at 
differentiating into osteoblasts in vivo [187]. However, co-transfection of BMP-2 and RUNX2 
into ADI-MSCs increased osteoblast differentiation in vitro and improved bone regeneration in 
vivo over BMP-2 transfection alone [188]. In contrast, RUNX2 over-expression in transgenic 
murine models has been associated with bone loss due to increased osteoclast differentiation 
[189] and osteoblastic MMP expression [190]. There is also concern over the role of RUNX2 as 
an oncogene in osteosarcoma and bone metastases [191]. Therefore, while the majority of 
research shows promise utilizing RUNX2 over-expression to improve osteogenic outcomes, 
caution must be taken as to the methodology and timing of the applications used. 
 OSX over-expression in murine embryonic stem cells was able to induce osteoblast 
differentiation by upregulating osteoblast-specific genes, and, in combination with osteogenic 
media additives, increase bone nodule formation [192]. Retroviral OSX over-expression in 
murine BM-MSCs enhanced osteoblast proliferation, differentiation, and mineralization in vitro 
[193]. A follow-up study used ex vivo OSX transfection of BM-MSCs implanted into a mouse 
calvarial critical defect model; the OSX vector stimulated five times more bone formation 
compared to empty vector controls [194]. In cells that are not predisposed to osteoblast lineage 
differentiation (NIH3T3 fibroblasts), OSX over-expression enhanced proliferation, but the 
expression of most osteoblast-specific genes and mineralization were not increased, suggesting 
that OSX alone is insufficient to establish osteogenic lineage commitment in cells not already 
‘inclined’ towards osteogenesis [195]. In an in vivo rabbit model of mandibular lengthening, 
BM-MSCs transfected with recombinant OSX plasmids enhanced callus formation and bone 
deposition during distraction osteogenesis compared to non-transfected BM-MSCs [196]. OSX 
over-expression in transgenic models increased osteoblast proliferation, yet it inhibited their late 
stage differentiation [129]. Of particular concern, the same study found that the OSX transgenic 
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mice developed osteopenia and increased fracture risk, due to collagen fiber orientation 
abnormalities resulting from impaired osteoblast differentiation [129]. As with RUNX2, further 
research is required to establish optimal timing and, perhaps as importantly, cessation of OSX 
over-expression in bone regeneration applications.  
 
Conclusions 
 There are many modalities utilized in bone regenerative medicine research that attempt to 
mimic and enhance the natural processes occurring during osteogenesis. Mesenchymal stem cells 
are the necessary cell source responsible for osteoblast differentiation, which must occur 
successfully in order to coordinate healing and repair of bone. The process of osteogenesis 
requires a tightly regulated orchestration by master transcription factors RUNX2 and OSX and 
multiple signaling pathways, most importantly through the TGF-β/BMP network. MSCs show 
strong potential for use in bone regenerative medicine, but their collection, propagation, and in 
vitro processing can vary significantly between species, making comparative analyses and 
clinical translation difficult to interpret accurately. Methods to improve the osteogenic capacity 
of MSC populations commonly include growth factor(s) supplementation and gene therapy 
techniques, both ex vivo and in vivo. There has been considerable success with exogenous BMP 
supplementation in various orthopedic surgical conditions, and other modalities of BMP 
signaling enhancement that are becoming more prevalent. Direct over-expression of RUNX2 or 
OSX in MSCs has yielded some improvement in osteogenic outcomes, but this approach appears 
to be less effective overall compared to BMP supplementation and can have detrimental effects 
depending on the technique used. Combinatorial approaches that enhance both BMP signaling 
and RUNX2 or OSX expression in MSCs may yield the best results, but optimization of 
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The Effects of General Anesthesia and Euthanasia on Equine Mesenchymal Stem Cell 
Viability, Proliferation, and In Vitro Osteogenic Capacity 
Abstract 
Multi-potent mesenchymal stem cells (MSCs) isolated from adult tissues, such as adipose 
(ADI) and bone marrow (BM), are promising sources for regenerative medicine therapies in both 
human and veterinary medicine. Tissues are typically collected from patients while they are 
under sedation or general anesthesia; however there is potential for collecting stem cells from 
recently deceased donors, somewhat analogous to organ donor programs, which would 
substantially increase the donor pool for allogeneic applications, in both veterinary and human 
medicine. The purpose of this study was to test the hypotheses that cell viability, proliferation, 
and in vitro osteogenic capacities of equine adult ADI- and BM-derived MSCs collected from 
anesthetized horses and shortly after euthanasia would be compromised compared to sedation-
collected controls. The results demonstrated that donor status during collection did not impact 
cell viability or in vitro proliferation. Further, osteogenic differentiation was not negatively 
impacted overall, as assessed by osteogenic gene expression, alkaline phosphatase (ALP) 
enzymatic activity, and Alizarin Red mineralized matrix staining. Some effects of donor status 
during collection on gene expression were evident at early time points, but this influence did not 
persist. In contrast to donor status during collection, all outcomes were strongly influenced by 
both inter- and intra-donor variability. Overall, equine adult MSCs collected during general 
anesthesia and shortly after euthanasia performed similarly to MSCs collected under sedation, 
thus supporting the collection of cadaver-sourced MSCs for allogeneic therapeutic applications.  
 
Introduction 
 Mesenchymal stem cells (MSCs) can be harvested and isolated from several adult tissues 
and body fluids [1 – 3]. They possess the ability to differentiate along multiple lineages [2, 4, 5], 
reduce inflammation at injury sites [6], and modulate host immune cell activities [7], thus 
making them an appealing source for regenerative medicine therapies [8]. In human medicine, 
MSCs for musculoskeletal applications are commonly isolated from bone marrow while the 
patient is anesthetized [9], but adipose tissue is also an abundant and easily harvestable 
alternative [10]. In veterinary medicine, MSC isolation techniques vary between species [1, 11, 
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12]. Horses are the veterinary species that utilize MSC-based therapies most extensively, due to 
their use as high-performance athletes and associated propensity for orthopedic injury [13, 14].  
Equine adipose (ADI) tissue and bone marrow (BM) aspirates can be collected from sedated 
horses [1], and the MSCs isolated from these sources have been successfully utilized in multiple 
clinical research scenarios for the healing of various musculoskeletal injuries [2, 11, 15 – 17]. 
There has been an interest in utilizing MSC-based therapies for targeting bone repair [17 – 18], 
especially in species such as horses that are prone to high morbidity and mortality rates due to 
fracture [13]. Optimizing MSC collection and isolation approaches, as well as in vitro osteogenic 
potential screening methods, can improve the use of MSCs in fracture healing. 
In both veterinary and human medicine, stem cell therapy is most often autologous in 
nature, meaning the donor is also the eventual recipient of the cells. This approach avoids the 
risk of immuno-rejection of the donor cells [19, 20]. However, there are many disadvantages 
surrounding the collection and use of autologous MSCs. Sample collection from live donors 
carries many risks for the patient, such as reaction to anesthesia, excessive bleeding, infection, 
disfigurement, and discomfort at the harvest site [21]. Human bone marrow collection can cause 
co-morbidities that may outweigh the benefits of any consequent MSC-based therapies [22, 23]. 
There is also considerable risk for the harvester working with veterinary species such as horses 
that often respond unpredictably during collection procedures. Further, the process of utilizing 
autologous MSCs involves extensive in vitro isolation and expansion to generate sufficient 
viable cells for clinical applications [9]. This can be problematic when therapy is necessary 
immediately to optimize clinical benefit, such as during a fracture repair scenario. Finally, MSCs 
from any given donor may be negatively altered by disease status, age, pharmaceutical agents, 
and other factors [24], thus making autologous MSC use a less than ideal option for some 
patients. Therefore, while autologous MSC may be the gold standard, there are many compelling 
reasons to explore allogeneic alternatives. 
The use of allogeneic MSCs banked from other donors provides for immediate 
therapeutic delivery that can be administered in conjunction with other procedures at the time of 
primary intervention. Current ethical and technical standards related to stem cell collection for 
allogeneic stem cell banking are not clear [25]. Recently deceased individuals have been 
proposed as a source for tissues and cells [26, 27], which could provide a large pool of donors 
while also avoiding many of the concerns related to collection morbidities [21 – 23], sample 
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quantity limitations [28], and regulatory protocol oversight at the institution level. Although 
there are known immuno-incompatibility issues with allogeneic grafts [29], these cells could be 
prospectively screened to minimize recipient rejection. However, it is uncertain whether MSCs 
collected while the donor is under general anesthesia or recently deceased behave equivalently to 
MSCs collected from conscious individuals, and whether experimental data derived from cells 
collected from anesthetized or recently deceased donors can be extrapolated to activities present 
in conscious donor cell populations [28, 30].  
The aims of this study were to compare the cell viability, proliferation, and osteogenic 
capacities of equine adult ADI- and BM-MSCs harvested from the same donor horses while 
under 1) standing sedation, 2) general anesthesia, and 3) shortly after euthanasia. The 
experiments were designed to test the hypotheses that equine MSCs collected during general 
anesthesia and after euthanasia would have decreased cell viability, proliferation, and osteogenic 
capacity, when compared to sedation-collected controls.  
 
Materials & Methods 
Research Animals 
 All procedures were approved by the University of Illinois Institutional Animal Care and 
Use committee (IACUC). Four healthy, adult horses (Table 3.1) were donated to the Veterinary 
Teaching Hospital for teaching and/or research purposes. Adipose tissue and bone marrow were 
collected sequentially from each horse while they were: 1) sedated but standing, 2) under general 
anesthesia in lateral recumbency, and 3) shortly after euthanasia.  
 
Sedation, Anesthesia, and Euthanasia Protocols 
 All horses were fasted overnight prior to the collection procedures. Horses were sedated 
with xylazine (1 – 2 mg/kg), and a 16-gauge intravenous catheter was placed in the jugular vein 
for administration of additional sedation and anesthetic drugs. For collection under sedation, 
horses were placed in stocks for restraint and given additional xylazine as required. The 
collection sites were cleaned and prepared once the horse showed signs of sedation and did not 
respond adversely to hair clipping and skin scrubbing.  
After collection of the “sedated” samples, the horses were anesthetized with a 
combination of ketamine (2.2 mg/kg) and midazolam (0.1 mg/kg) administered IV through the 
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jugular catheter. Horses were placed in lateral recumbency, and an endotracheal tube was 
inserted for mechanical ventilation and anesthesia maintenance with isoflurane. Vital parameters 
were monitored using electrocardiogram (ECG), pulse oximetry, and direct arterial blood 
pressure and blood gas sampling via a 20-gauge catheter placed in the transverse facial artery. 
Horses under general anesthesia were allowed to stabilize until an appropriately deep anesthetic 
plane was reached and maintained for at least 5 minutes.  
After collection of the “anesthesia” samples, the horses were euthanized while still under 
general anesthesia using an IV bolus of pentobarbital (10 – 15 ml / 100 lb body weight). Death 
was confirmed by cardiac auscultation, ECG, and a negative corneal reflex response. 
“Euthanasia” samples were collected approximately 5 – 10 minutes after death was confirmed. 
 
Adipose Tissue Collection & Processing 
For adipose tissue collection, the skin adjacent to the tail head was clipped and cleaned 
with chlorohexidine and ethanol. The collection site was desensitized using 1% lidocaine 
subcutaneously (10 – 20 ml) until the horse did not respond to pressure from a hemostat. A 5 – 
10 cm skin incision was made into the subcutaneous adipose depot lateral to each tail head. 
Approximately 8 – 10 grams of adipose tissue was removed and immediately placed into sterile 
cell culture growth media [1X Dulbecco’s modified Eagle’s medium (DMEM), 10% fetal bovine 
serum (FBS), 100 U/ml penicillin, and 100 streptomycin μg/ml (1% P/S)]. The skin incision was 
closed with monocryl suture material. Additional samples collected under general anesthesia and 
after euthanasia were harvested from sites adjacent or contralateral to the initial site. 
Adipose tissue samples were diced into small pieces and digested in cell culture media 
(10 ml per 1 gram of tissue) containing 0.2% collagenase type II (Worthington Biochemical 
Corporation) for 3 hours in an orbital shaker at 37
o
C. The digest was triturated via pipette during 
the incubation, to facilitate cell dispersion. After digestion, the cells were filtered through 70 μm 
and 40 μm mesh filters, and then centrifuged at 300 x g for 10 minutes (Sorvall ST 16R 
Centrifuge, Thermo Scientific). The number of primary adipose cells was determined using a 
hemocytometer with cellular viability assessed via Trypan Blue exclusion. The isolated adipose 




 in growth media and 
maintained in an incubator at 37
o
C in 5% CO2 and 90% humidity. Media was changed every 2 – 




Bone Marrow Collection & Processing 
For bone marrow aspiration, the skin of the ventral sternum region was clipped and 
aseptically prepped. The 5
th
 sternebra was chosen as the collection site during standing sedation, 
which is located approximately 8 cm caudal to the point of the elbow. The area was blocked 
using 1% lidocaine subcutaneously and near the periosteum (5 – 10 ml). A small stab incision 
was made through the skin using a #11 scalpel blade. A 12-gauge Jamshidi needle was 
introduced into the stab incision and advanced approximately 1 – 2 cm through the cortical bone 
and into the medullary cavity of the sternebra. A 12-ml syringe preloaded with approximately 
5000 IU of heparin was connected to the Jamshidi needle and used to slowly aspirate 10 – 15 ml 
of bone marrow. The syringe was inverted several times, and then the bone marrow aspirate was 
transferred asceptically to a 50-ml sterile conical tube. Additional samples collected under 
general anesthesia and after euthanasia were harvested from sternabrae adjacent to the initial site. 
Bone marrow aspirates were mixed and suspended in PBS containing 1% P/S, then 
centrifuged at 1000 x g for 15 minutes (Sorvall ST 16R Centrifuge, Thermo Scientific) to pellet 
the cellular contents. All but approximately 5 ml of the supernatant was aspirated, and the pellet 
was resuspended in growth media and transferred to two adherent T-75 cm
2
 cell culture flasks. 
Additional media was added to a total volume of 15 – 20 ml per flask. Flasks were placed in an 
incubator at 37
o
C in 5% CO2 and 90% humidity. To allow adequate time for bone marrow (BM) 
MSCs to settle out of the suspension and adhere to the cell culture flask, only a small portion of 
the media was changed every 2 – 3 days for the first week. The process involved rocking the 
flask back and forth several times to loosen red blood cells and other non-adherent debris, then 
tilting the flask on its side for 5 minutes to allow heavier contents to settle toward the bottom. 
About half of the supernatant was removed and replaced with 10 ml fresh growth media. After 
the first week, the remaining media/cell suspension was completely removed and the flask 
surface washed with PBS + 1% P/S before refeeding with growth media, which was changed 
every 2 – 3 days until the adherent cells reached 80 – 90% confluence. 
 
Cellular Expansion & Proliferation Assays 
 When MSCs reached near-confluence, they were passaged via trypsinization. Growth 
media was first removed, and the culture vessel rinsed with 1X PBS + 1% P/S. An appropriate 
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volume of 0.5% trypsin-EDTA was added to the vessel, which was then placed in an incubator at 
37
o
C for 5 minutes. The vessel was briefly agitated to assess cell detachment, and then growth 
media (1X DMEM, 10% FBS, 1% P/S) was added to deactivate the trypsin. A small volume of 
the cell suspension was used to make a 1:10 dilution in cell counting solution (10% Trypan blue 
in 1X PBS). A volume of 10 μl was added to each side of the hemocytometer, and the total 
number of viable cells (i.e., those that do not absorb Trypan blue) was counted: 
 Total number of live cells/ml = (# of live cells counted / # of squares) x 10 (cell dilution 
factor) 10
4
 (hemocytometer surface area factor) 
 Total number of live cells = # of cells/ml x volume of cell suspension 
 Cell viability = # of live cells / (# dead cells + # live cells) 
 
All primary MSCs were expanded through 3 passages. The number of cells isolated from the 
initial collections, if known, the numbers seeded and recovered at each passage, and the time 
required for expansion to confluence were recorded. These values were used to calculate the 
population doublings and population doubling times [31]: 
 Population doublings (PDs) during each passage =  Log2 (harvested cell # / seeded cell #) 
 Population doubling time (PDT) = time between passages / PDs during each passage 
 
In Vitro Osteogenesis 
 Third passage (P3) MSCs were seeded at 2,000 cells/cm
2
 in cell culture plates and 
maintained in growth media (1X DMEM, 10% FBS, 1% P/S) until approximately 50% 
confluence was reached. Control (Cx) cultures remained in growth media, while osteogenic 
cultures were transferred to osteogenic induction media (OIM), which consisted of a growth 
media base supplemented with 50 μg/ml L-Ascorbic Acid Phosphate Magnesium Salt n-Hydrate 
(Wako, Japan), 10 mM β-Glycerophosphate (Sigma-Aldrich), and 100 nM Dexamethasone 
(Sigma-Aldrich). ADI-MSCs in OIM were also supplemented with 100 ng/ml recombinant 
human bone morphogenetic protein (BMP)-2 (Gemini Biosciences) based on preliminary results. 
Cultures were maintained for up to 10 days. Media was replaced every 2 – 3 days, and 
representative images of the cultures were recorded via digital light microscopy. Cells were 
collected for Alizarin Red staining, RNA isolation for gene expression analyses, and alkaline 




Alizarin Red Staining 
 A 2% Alizarin Red-S (Sigma-Aldrich) solution was prepared in ddH2O and adjusted to a 
pH of 4.1 – 4.3 using an UltraBASIC UB-5 pH meter (Denver Instrument). The stain was filter-
sterilized to remove any debris and stored at 4
o
C when not in use.  
 Cells in 6-well plates were washed in 1X PBS + 1% P/S, and then fixed with 4% 
paraformaldehyde for 30 minutes at room temperature. Wells were washed three times with 
ddH2O, and 1 ml of 2% Alizarin Red-S stain was applied. Plates were incubated for 20 minutes 
at room temperature on a plate shaker to distribute stain evenly. Excess stain was removed with 
repeated ddH2O rinses, and stained cells were imaged dry using a DMIL microscope, PFC320 
digital camera, and supporting Leica Application Suite (LAS Version 2.6.R1) software (LEICA).  
A positive Alizarin Red stain was indicated by a red color uptake into the cellular matrix, while a 
negative stain maintained a dull brownish color, even when sequestered in cellular aggregates.  
 
RNA Isolation & Quantification 
 Cells in 2 – 3 wells of a 6 well plate were collected and pooled for RNA isolation using 
the phenol-based dissociation agent, TRIzol® (Life Technologies). Media was removed, and 
each well was washed with 1X PBS + 1% P/S. TRIzol® reagent was applied directly to the cell 
monolayers, and the lysates were scraped from the vessel surface and transferred to 15 ml 
conical tubes. Tubes were placed on ice, and then homogenized for 30 seconds using an Ultra-
Turrax T25 homogenizer (Janke & Kunkel, IKA Labortechnik). Samples were stored at -80
o
C. 
 RNA isolation was performed according to the recommended TRIzol® reagent protocol. 
Lysates were first transferred to a 1.5 ml microcentrifuge tube. For every 1 ml TRIzol® reagent 
used, 200 μl of chloroform (Sigma-Aldrich) was added. Samples were vortexed for 15 seconds, 
and then allowed to separate at room temperature for 2 – 3 minutes. Following centrifugation at 
12,000 x g at 4
o
C for 15 minutes (Centrifuge 5415 R, Eppendorf), the upper, aqueous portion 
(approximately 400 – 500 μl) was transferred to a new 1.5 ml microcentrifuge tube. The interface 
and lower portions, containing insoluble proteins, lipids, and DNA, were discarded. 
 RNA within the aqueous phase was precipitated by adding 500 μl isopropanol and 
incubating at -20
o
C overnight. The next day, the samples were centrifuged as before, resulting in 
the precipitation of a translucent pellet. The supernatant was removed, and the pellet was washed 
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with 1 ml of 75% ethanol to reduce the salt content of the pellet. The samples were briefly 
vortexed to detach the pellet from the tube wall, and then centrifuged at 7,500 x g for 5 minutes 
at 4
o
C. The ethanol wash supernatant was removed, and the pellet was allowed to air-dry for 
approximately 5 – 10 minutes. Any remaining liquid was carefully removed, and the RNA pellet 
was resuspended in nuclease-free water (NF-H2O) at a volume appropriate for the estimated 
pellet size (typically 50 – 100 μl). The tubes were vortexed, spun down briefly, and then 
incubated in a 65
o
C water bath for 10 minutes. RNA samples were immediately quantified using 





 RNA was reverse transcribed into cDNA using the SuperScript
TM
 IV First-Strand 
Synthesis System kit (Invitrogen). One microgram of each RNA sample was brought up to 11 μl 
total volume with diethyl pyrocarbonate (DEPC)-treated water. A master mix containing 1 μl of 
50 μM oligo(dT)20 and 1 μl of 10 mM dNTP mix per sample was made, and 2 μl of this master 
mix was added per sample. Tubes were vortexed and quick spun down, and then incubated in a 
65
o
C water bath for 5 minutes. Tubes were removed and chilled on ice for at least 1 minute. A 
second master mix was made, which contained 4 μl of 5X SSIV Buffer, 1 μl of 100 mM DTT, 1 
μl of 40 U/μl Ribonuclease inhibitor, and 1 μl of 200 U/μl SuperScript IV reverse transcriptase 
(RT) enzyme. Seven microliters of the second master mix were added per sample, and the tubes 
were briefly spun down. For the reverse transcription reaction, tubes were incubated in a 55
o
C 
water bath for 20 minutes. The RT reaction was inactivated by placing the samples in an 80
o
C 
water bath for 10 minutes. RNA was removed by treating each sample with 2 units of E. coli 
RNase H and incubating in a 37
o
C water bath for 30 minutes. Final cDNA samples were diluted 
1:10 by adding 189 μl NF-H2O, and the samples were stored at -20
o
C until qPCR. 
 
Primers & Gradient PCR 
 Samples were assessed for their relative expression of major osteogenic genes: runt-
related transcription factor 2 (RUNX2), osterix (OSX), and alkaline phosphatase (ALP). 
Elongation factor 1 alpha-1 (EF1α) was used as a reference gene. Primer sequences were 
designed using NCBI-BLAST software and purchased from Integrated DNA Technologies 
(IDT). See Table 3.2 for primer sequences and optimal annealing temperatures. 
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 Lyophilized primers were reconstituted in 1X TE (10 mM Tris-HCl, 1 mM EDTA, pH 
8.0) buffer to generate a 100 μM stock solution, which was further diluted 1:10 in NF-H2O to 
yield a 10 μM working stock. Optimum annealing temperatures were determined by gradient 
PCR and subsequent gel electrophoresis to assess product band quality and intensity. 
Approximately 100 ng of a positive control cDNA sample expected to express detectable levels 
of the primer target was used. Each PCR reaction contained 2.5 μl of 10X PCR Buffer, 1 μl of 10 
mM MgCl2, 0.5 μl of 10 mM dNTP mix, 0.3 μl of Taq polymerase (Life Technologies), and NF-
H2O to a final volume of 23 μl. A master mix of each 1:10 diluted primer set contained equal 
volumes of sense and anti-sense primer, which was added at 2 μl per reaction.  
 Gradient PCR amplification was performed using an iCycler iQ
TM
 thermocycler (BIO-
RAD) at various annealing temperatures ranging from 50 – 65
o
C. Following PCR amplification, 
10 μl of each sample was mixed with 2 μl of Blue/Orange 6X loading dye (Promega), and 10 μl 
of this mixture was added to a well in a 2% agarose (Fisher BP160-100) gel in 1X TAE buffer 
(1:50 diluted 50X stock solution: 242 g Tris base, 57.1 ml glacial acetic acid, 100 ml of 500 mM 
EDTA, pH 8.0, to a final volume of 1L in ddH2O) containing 0.5 mg/ml ethidium bromide 
(Sigma) submersed in 1X TAE running buffer. A volume of 2 – 3 μl TrackIt
TM
 1Kb Plus DNA 
ladder (Invitrogen) was added per lane. Gels were run in a Midi-Horizontal Electrophoresis 
System (Fisher Biotech, FB-SB-1316) at 100 V constant using a Power Station 300 (Labnet) 
power source for approximately 1 – 2 hours or until desired distance was reached. Upon 
completion, gels were imaged using the Molecular Imager ChemiDoc
TM
 XRS+ (BIO-RAD) and 
corresponding Image Lab software (BIO-RAD). Band intensity was compared across 
temperatures to determine which produced a single product and most-intense band.  
 
Primer Concentrations & Efficiency 
 Primers utilized in the qPCR reactions were tested for optimal reaction concentration by 
testing several dilutions of primers with a known quantity of cDNA at an optimum annealing 
temperature determined from gradient PCR. The optimal primer concentration in the qPCR 
reaction was determined based on which dilution yielded the lowest CT values for that primer set.  
 Primer efficiency was evaluated by testing the single best primer concentration on 
serially-diluted cDNA samples of known concentration. The CT values obtained were plotted 
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against the Log10 of the cDNA dilution factor. A linear fit equation (y = mx + b, R
2
) was 
determined using Microsoft Excel. Results were analyzed based on the following criteria: 
 PCR efficiency of 100% = slope of -3.32 
o A “good” reaction has an efficiency between 90 – 110%, which corresponds to 
slope values between -3.58 and -3.10. 
 Amplification Efficiency = 10(-1/slope) – 1 
 % Efficiency = Amplification Efficiency x 100 
 
Quantitative Real-Time PCR 
 Quantitative real-time PCR (qPCR) was performed using 5 μl of 1:10 diluted cDNA 
samples added to 20 μl of a master mix comprised of 12.5 μl iQ
TM
 SYBR® Green Supermix 
(BIO-RAD), 2 μl each of 1:10 diluted sense and antisense primer (0.4 μM final concentration), 
and 3.5 μl NF-H2O. A “no template control” reaction was performed for each primer, containing 
5 μl of NF-H2O instead of cDNA. The qPCR reactions were performed using the iCycler iQ
TM
 
thermocycler (BIO-RAD) and iCycler Optical Module (BIO-RAD), which was run and 
subsequently analyzed using iCycler iQ
TM
 software (BIO-RAD). The presence of a single PCR 
amplicon was determined by melting curve analysis, and in select cases, gel electrophoresis. 
Amplicons were sequenced during the initial optimization protocols to ensure correct targeting.  
Quantitative PCR data were analyzed using the 2
-ΔΔCT 
method [32]. The CT values for the 
constitutively reference gene, EF1α, were used to normalize CT values of the experimental 
transcripts. The corrected CT value of the sedation-collected control sample from each collection 
time point was then subtracted from each sample to produce the comparative ΔCT value. The 
final relative fold change in expression levels was determined by 2
(- comparative ΔCT value)
. This 
equation results in the reference control sample yielding a value of 1, while each treatment 
sample’s value will vary depending on the relative change in expression of the target gene. For 
primer sets with a less than 90% efficiency, the equation was adjusted to 1.99
(- comparative ΔCT value)
. 
 
Alkaline Phosphatase Enzymatic Assay 
 Cells were lysed in 1 ml of 2% Triton X-100 in 1X TE Buffer (10 mM Tris-HCl, 1 mM 
EDTA, pH 8.0). In some cases, samples were from a single well of a 6-well plate, pooled from 2 
wells of a 12-well plate, or collected as individual replicates from a 12-well plate. Surface area of 
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sample collection and dilution adjustments were taken into account during the assay analyses. 
Cell lysates were transferred to 2 ml microcentrifuge tubes and stored at -20
o
C until processing. 
 Samples were transferred to glass tubes and homogenized for 15 – 30 seconds using an 
Ultra-Turrax T25 homogenizer (Janke & Kunkel, IKA Labortechnik). Homogenate was 
transferred into a microcentrifuge tube, left on ice for 30 minutes, and then centrifuged at 2,500 
rpm and 4
o
C for 15 minutes (Centrifuge 5415 R, Eppendorf). The supernatant was transferred to 
a new microcentrifuge tube and stored at -20
o
C until the assay was performed. 
 ALP activity was assessed using the LabAssay
TM
 ALP kit (Wako) following the 
manufacturer’s instructions. The assay uses a p-nitrophenyl phosphate substrate, which is 
hydrolyzed into p-nitrophenol and phosphoric acid in the carbonate buffer when alkaline 
phosphatase is present in the sample. Working assay solution was made by dissolving a p-
nitrophenyl phosphate tablet in 5 ml Buffer Solution (2.0 mmol/L MgCl2, 0.1 mol/L Carbonate 
Buffer, pH 9.8), producing a final concentration of 6.7 mmol/L. A standard curve was produced 
by serial dilutions of the Standard Solution (0.5 mmol/L p-nitrophenol). Twenty microliters of 
each standard and sample was added to a transparent 96-well microplate (Corning), and then 100 
μl of working assay solution was added per well. The plate was briefly agitated to mix contents, 
and then placed in an incubator at 37
o
C for 15 minutes.  After incubation was complete, 80 μl of 
Stop Solution (0.2 mol/L Sodium Hydroxide) was added to each well to deactivate the reaction. 
The reaction generated a yellow color change, which was optically measured at 405 nm 
wavelength using a FLUOstar OPTIMA microplate reader and supporting software (BMG). 
 To determine the amount of p-nitrophenol product in each sample, a standard curve and 
linear fit equation was generated. The concentration was initially calculated as mmol/L, which is 
equivalent to nm/μl.  The activity was calculated as follows: 
 ALP Activity (units/μl) = (C / RT) x DF 
o C = concentration of p-nitrophenol released relative to standard curve (nm/μl) 
o RT = reaction time, which was 15 minutes 
o DF = dilution factor, which was considered ‘1’ unless the sample was pre-diluted 
 
The ALP activity of each sample was normalized to its DNA content by dividing the activity 
(units/μl) by the DNA concentration (μg/μl), as determined in a separate assay. The final data 




DNA Quantification Assay 
 Samples for DNA quantification were the same as those processed and used for the ALP 
activity assay above. DNA quantification was performed using the Quant-iT
TM
 PicoGreen® 
dsDNA kit (Invitrogen) based on the manufacturer’s instruction manual.  
 A working solution of 1:200 diluted Quant-iT
TM
 PicoGreen® reagent in 1X TE Buffer 
(provided in kit at 20X and diluted with NF-H2O) was made and kept protected from light. The 
DNA standards were prepared by using the lambda (λ) DNA standard provided in the kit and 
making a 12-point serial dilution in 1X TE Buffer. A volume of 100 μl of each standard and 
sample were added to a black-sided, clear-bottom 96-well plate (Corning). The working solution 
was added at a volume of 100 μl per well, the plate was covered to protect from light, and the 
plate was mixed briefly and incubated for 5 minutes at room temperature. Fluorescence was 
measured at 485 nm excitation wavelength using a FLUOstar OPTIMA microplate reader and 
supporting software (BMG). 
To determine the amount of DNA in each sample, a standard curve and linear fit equation 
were generated. The concentration was initially calculated as μg/ml, which was divided by 1000 
and converted to μg/μl. This value was then used to normalize the ALP activity, as described. 
 
Statistical Analyses 
 All data were analyzed using GraphPad Prism (GraphPad Software, INC) and expressed 
as mean + the standard error of the mean (SEM). Data were evaluated for normality using the 
Kolmogorov-Smirnov, D’Agostino and Pearson, and Shapiro-Wilk normality tests, where 
appropriate. Normally distributed data were analyzed using the tests mentioned below for each 
comparison. If data was not normally distributed or normality could not be determined due to 
small sample size, a corresponding non-parametric test was also performed. Statistical significant 
was assigned at p < 0.05 with n = 3 – 4 separate experiments (horses).  
The effect of donor variability or donor status during collection on primary cell counts 
was analyzed via One-Way Analysis of Variance (ANOVA). Dunnet’s post-hoc tests were 
performed to compare anesthesia- and euthanasia- to sedation-collected controls. 
The effect of passage number, donor variability, and donor status during collection on 
population doubling time was analyzed via 2-Way Repeated Measures ANOVA. Bonferonni 
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post-hoc tests were performed to compare anesthesia- and euthanasia-collected samples to 
sedation-collected controls. 
The effect of culture treatment and donor status during collection on osteogenic gene 
expression and ALP activity levels were evaluated at each culture time point using 2-Way 
ANOVA. Bonferonni post-hoc tests were performed to compare anesthesia- and euthanasia-
collected samples to sedation-collected controls. The effect of time post-osteogenic induction on 
osteogenic gene expression and ALP activity level outcomes within each culture treatment group 




The four horses used in this study consisted of three intact females and one castrated 
male, and they varied in age between 2 and 9 years and Body Condition Scores (BCS) of 3 to 7 
out of 9 (Table 3.1). There were no systemic health concerns in any of the four horses. Three 
samples were lost from the study. Horse 1 could not have an adipose sample collected under 
sedation due to technical difficulties. Horse 3 lost the euthanasia-collected BM-MSC sample 
during cell culture due to senescence. Horse 4 lost the sedation-collected BM-MSC sample due 
to contamination that could not be treated with additional antimicrobials. 
 
Sample Collection 
 Adipose tissue specimens ranged from 7.41 to 17.91 grams. The mean (SEM) weight in 
grams of tissue collected was 8.603 (0.6077) for sedation-, 6.250 (1.640) for anesthesia-, and 
11.39 (3.298) for euthanasia-collected adipose tissue. There was no statistically significant 
difference between the collected adipose tissue weights (data not shown). 
Bone marrow aspirate volumes ranged from 6 to 12 ml. The mean (SEM) volume in 
milliliters (ml) was 10.25 (1.346) for sedation-, 10.00 (1.225) for anesthesia-, and 8.250 (2.175) 
for euthanasia-collected aspirates. There was no statistically significant difference between the 




Primary Cell Counts 
ADI-MSC primary cell yields were calculated as ‘cells/gram of tissue’. The mean (SEM) 
yields were 1.26 x 10
6
 (441,966) for sedation-, 2.34 x 10
6
 (895,473) for anesthesia-, and 2.02 x 
10
6 
(792,783) for euthanasia-collected samples (Figure 3.1). Donor variability significantly 
impacted ADI-MSC primary cell yields (p = 0.0002), but donor status during collection did not 
(Figure 3.1). Horses 1 and 4 differed significantly from Horses 2 & 3 across all collection 
statuses (p < 0.05). Horses 1 and 4 had lower BCSs, while Horses 2 & 3 had higher BCSs. Lower 
BCSs resulted in higher primary cell yields from the adipose tissue, but this was observation not 
statistically evaluated. 
BM-MSC primary cell yields were determined by counting the cells after they had 
reached near confluence, prior to the first passage, and were adjusted for the initial bone marrow 
aspirate volume (ml) and days to confluence. The mean (SEM) of the primary cells / ml of 
aspirate for each collection status was 1.27 x 10
6
 (82,550) for sedation-, 1.65 x 10
6
 (75,182) for 
anesthesia-, and 1.88 x 10
6 
(66,154) for euthanasia-collected samples (Figure 3.2). Donor 
variability significantly impacted BM-MSC primary cell yields (p = 0.0034), but donor status 
during collection did not (Figure 3.2). Horse 1 differed significantly from Horse 3, and Horse 4 
differed significantly from Horses 2 & 3 (p < 0.05).  
In summary, donor variability significantly impacted primary cell yields in both ADI- 
and BM-MSCs, while donor status during collection did not. 
 
Days to Confluence & Cell Yields 
In ADI-MSC, days to confluence were highest in primary cell cultures and decreased in 
passages 1 and 2, but these differences were not statistically significant (data not shown). Cell 
yields generally increased with passage number. Passage significantly influenced cell yield (p = 
0.0329), but donor status during collection did not (data not shown).  
In BM-MSCs, days to confluence were also highest with the primary cell cultures and 
decreased in passages 1 and 2. Passage significantly impacted days to confluence (p < 0.0001), 
but donor status during collection did not (data not shown). End of passage cell counts increased 
with passage number in sedation-collected samples only. Neither passage nor donor status during 




Population Doubling Times 
Population doubling time (PDT) was calculated for each passage within each donor status 
during collection (Figure 3.3). 
In ADI-MSCs (Figure 3.3, top), the mean (SEM) of PDTs for all passages was 2.72 
(0.4540) for sedation-, 1.964 (0.2470) for anesthesia-, and 1.987 (0.2653) for euthanasia-
collected samples. PDT was significant affected by passage (p = 0.0002) and donor variability (p 
= 0.0164), but not donor status during collection. 
In BM-MSCs (Figure 3.3, bottom), the mean (SEM) of the PDT for all passages was 
1.812 (0.2133) for sedation-, 2.371 (0.3615) for anesthesia-, and 1.942 (0.2586) for euthanasia-
collected samples. Primary cell PDTs could not be calculated due to an unknown starting number 
of primary cells in the bone marrow aspirate. There were no significant effects of passage, donor 
variability, or donor status during collection on PDT. 
In summary, passage number and donor variability significantly affected PDTs in ADI-
MSCs only. Donor status during collection did not affect PDTs in either cell type. 
 
Multi-Cellular Aggregation & Alizarin Red Staining Observations 
  ADI-MSCs were generally less responsive to osteogenic induction compared to BM-
MSCs; they showed less multi-cellular aggregation and minimal Alizarin Red stain uptake, even 
at later time points. Only one ADI-MSC OIM + BMP-2 culture treatment group showed multi-
cellular aggregation into large nodules that stained positive for Alizarin Red by Day 10 (data not 
shown). Conversely, in ADI-MSC cultures that did not show distinct multi-cellular aggregation 
or stain positively for Alizarin Red in osteogenic conditions, BMP-2 supplementation had little 
to no effect over osteogenic media alone (Figure 3.4).  
BM-MSCs were more responsive to osteogenic induction compared to ADI-MSCs, 
consistent with previous data. Of the four horses, only one had BM-MSCs survive in osteogenic 
media to the Day 10 collection time point (Figure 3.5). This horse showed dense cellular 
aggregation and strong Alizarin Red stain uptake in OIM compared to Cx cultures. Alizarin Red 
staining even leached out of aggregates to create a weak pink background in blank areas of the 
plate well. The BM-MSC cultures that did not survive in osteogenic media showed accelerated 
cellular aggregation and cell death and detachment by days 7 – 8, but no evidence of 
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mineralization (data not shown). Alizarin Red staining was not performed at the later time point 
in these samples, as all plate wells were pooled for RNA sample collection. 
Allowing for the somewhat subjective nature of these observations, there was an obvious 
effect of donor variability, but not donor status during collection, on the subsequent multi-
cellular aggregation behavior and Alizarin Red staining observed in either ADI- or BM-MSCs 
undergoing osteogenesis that survived to the later Day 10 time point. 
 
Osteogenic Gene Expression: ADI-MSCs 
RUNX2 expression in ADI-MSCs (Figure 3.6) was significantly affected by culture 
treatment at both Day 5 (p < 0.0001) and Day 10 (p = 0.0080), with increased transcript levels 
present in the OIM and OIM + BMP-2 culture treatment groups compared to the Cx culture 
treatment group. At Day 5, RUNX2 was also significantly impacted by donor status during 
collection (p = 0.0292), with a significant decrease in RUNX2 transcript levels observed in the 
euthanasia-collected group compared to sedation-collected control group within the OIM + 
BMP-2 culture treatment (p < 0.05). However, the effect of donor status during collection was no 
longer significant at Day 10. RUNX2 expression did not significantly differ within any of the 
culture treatment groups between Day 5 and Day 10.  
OSX expression in ADI-MSCs (Figure 3.7) was not significantly affected by culture 
treatment or donor status during collection at either time point. OSX expression did not 
significantly differ within any of the culture treatment groups between Day 5 and Day 10. 
ALP expression in ADI-MSCs (Figure 3.8) was significantly affected by culture 
treatment at both Day 5 (p = 0.0095) and Day 10 (p = 0.0124), with increased transcript levels in 
the OIM and OIM + BMP-2 culture treatment groups compared to the Cx culture treatment 
group. Donor status during collection did not significantly affect ALP expression at either time 
point. ALP expression did not significantly differ within any of the culture treatment groups 
between Day 5 and Day 10. 
In summary, donor status during collection only significantly affected RUNX2 
expression at the earlier Day 5 time point, with a significant decrease in RUNX2 transcript levels 
seen in euthanasia-collected samples. Culture treatment significantly affected RUNX2 and ALP, 
but not OSX, at both time points. Time post-osteogenic induction did not result in a significant 
difference in RUNX2, OSX, or ALP expression within any culture treatment group. Collectively, 
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the results also indicate that exogenous BMP ligand is required to stimulate osteogenic gene 
expression in ADI-MSCs. 
 
Osteogenic Gene Expression: BM-MSCs 
RUNX2 gene expression in BM-MSCs (Figure 3.9) was significantly affected by culture 
treatment at both Day 5 (p = 0.0131) and Day 10 (p = 0.0278), with increased transcript levels 
present in the OIM compared to Cx culture treatment groups. Donor status during collection did 
not significantly affect RUNX2 expression at either time point. RUNX2 expression did not 
significantly differ within either culture treatment group between Day 5 and Day 10. 
OSX expression in BM-MSCs (Figure 3.10) was significantly affected by culture 
treatment only at the later Day 10 time point (p = 0.0248), with increased transcript levels 
present the OIM compared to Cx culture treatment groups. Donor status during collection did not 
significantly affect OSX expression at either time point. OSX expression did not significantly 
differ within either culture treatment group between Day 5 and Day 10. 
ALP expression in BM-MSCs (Figure 3.11) was significantly affected by culture 
treatment at both Day 5 (p = 0.0223) and Day 10 (p = 0.0050), with increased transcript levels 
present the OIM compared to Cx culture treatment groups. Donor status during collection did not 
significantly affect ALP expression at either time point. ALP expression was significantly 
increased within the OIM culture treatment group at Day 10 compared to Day 5 (p = 0.0330). 
In summary, donor status during collection did not significantly affect any of the 
osteogenic genes at either time point in BM-MSCs. Culture treatment significantly affected 
RUNX2 and ALP at both time points and OSX at the later time point. Time post-osteogenic 
induction resulted in a significant increase in ALP expression in the OIM culture treatment 
group, but not RUNX2 or OSX expression. 
 
Alkaline Phosphatase (ALP) Bioactivity Assay 
ALP activity in ADI-MSCs (Figure 3.12) was not significantly affected by culture 
treatment or donor status during collection at either time point. Euthanasia-collected samples 
showed higher and more variable ALP activity levels at the Day 10 time point, but the difference 
was not statistically significant. ALP activity levels did not significantly differ within any of the 
culture treatment groups between Day 5 and Day 10. 
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 ALP activity in BM-MSCs (Figure 3.13) was significantly affected by culture treatment 
only at the later Day 10 time point (p < 0.0001), with increased ALP activity seen in OIM 
compared to Cx culture treatment groups. There was no significant effect of donor status during 
collection on ALP activity at either time point. ALP activity was significantly increased in the 
OIM culture treatment group at Day 10 compared to Day 5 (p = 0.0002). 
 In summary, ALP activity was not impacted by culture treatment, donor status during 
collection, or time post-osteogenic induction in ADI-MSCs. ALP activity was significantly 
impacted by culture treatment and time post-osteogenic induction in BM-MSCs, but not donor 
status during collection. 
 
Discussion 
 This study compared the in vitro cellular viability, proliferation, and osteogenic 
differentiation capacity of equine adult ADI- and BM-MSCs collected during standing sedation, 
general anesthesia, and post-euthanasia. The hypothesis was that general anesthesia and 
euthanasia would negatively impact the in vitro behavior of MSCs compared to sedation-
collected controls. The results do not support the hypothesis, indicating that general anesthesia 
and euthanasia do not negatively impair MSC behavior in vitro and can be considered equivalent 
methods for collection of MSCs from adipose tissue and bone marrow. 
 The cell viability and proliferation outcome measures used in this study were not 
influenced by donor status during collection of the sample. There is growing suspicion that 
certain anesthetic drugs impair neurogenesis, which may contribute to post-anesthetic cognitive 
dysfunction, especially in older individuals [34]. Studies evaluating the effects of prolonged 
anesthesia with various anesthetic agents in young and aged rats have shown mixed results as to 
the effect on neuronal cell proliferation [35 – 37]. Therefore, it is likely that any deleterious 
effects of general anesthetic agents on cell proliferation are localized to neuronal tissues due to 
their mechanisms of action. This would explain why effects were not seen in adipose or bone 
marrow samples. Alternatively, the time of general anesthesia in this study may not have been 
long enough to allow significant compromise from the anesthetic agents or physiological effects 
following general anesthesia.  
Viable MSCs have been successfully isolated from diseased donors, such as human 
cadaver tissues within 24 hours after death [38], bovine fetal bone marrow from an abattoir [39], 
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and equine bone marrow within 30 minutes post-euthanasia [40]. In all three studies, the cells 
displayed in vitro behavior characteristics of and appropriate cell surface markers for multipotent 
MSCs [41, 42].  The outcomes here are consistent with these published findings and extend the 
assessment to the process of osteogenic differentiation. Clearly, the impact of anesthesia and 
donor death on other lineage differentiation capacities was not addressed. In light of the 
recognized impact of anesthetic agents on neuronal cell functions, the effects of anesthesia and 
euthanasia on neuronal progenitors warrant further investigation. 
Some cell proliferation parameters were significantly impacted by passage number. It has 
long been laboratory dogma that trypsinization can help “boost” cell cultures into increasing 
proliferation rates initially, whereas extending time to passage can negatively impact population 
doubling times and long-term cell viability [43]. In this context, it was not surprising to see that 
‘days to confluence’ tended to decrease while ‘end of passage cell counts’ tended to increase 
with each subsequent passage. Had the experiment been taken out to longer passages, these 
trends may have regressed due to cell senescence [44]. It is also not surprising that ‘population 
doubling times’ also tended to decrease with passage given that this parameter is a function of 
both days to confluence and end of passage cell counts.  
The initial primary cell numbers and viability likely influenced subsequent proliferative 
behavior. For example, BM-MSCs from Horse 1 had the shortest days to confluence across all 
passages compared to Horses 2 – 4, which would suggest that either the starting primary cell 
counts were higher or the cell proliferative ability was superior. It is also important to note that 
Horse 1 was the youngest donor, at 2 years of age, and increasing age has been shown to 
negatively impact number of viable MSCs and cell proliferative capacities in human donors [45 
– 47]. Some studies have evaluated age-related effects on MSC behavior in veterinary species 
[48 – 50], but more investigation would be necessary in order to establish criteria for eligible 
donors to allogeneic stem cell banks.  
Osteogenic capacity of both ADI- and BM-MSCs was not impacted by donor status 
during collection, which was not surprising given that cell viability and proliferation were 
similarly unaffected. In general, BM-MSCs were more osteogenic than ADI-MSCs in osteogenic 
media alone, consistent with previous studies. However, cells from different donors and statuses 
during collection often had different osteogenic responses, and it was not consistent within 
donors and between cell types. For example, Horse 1’s BM-MSCs had a robust osteogenic 
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response, while Horse 2 had a single ADI-MSC sample that responded well to osteogenic media 
supplemented with BMP-2. These results graphically demonstrate that both inter- and intra-
donor variability greatly influence MSC differentiation outcomes, with factors such as primary 
cell number, proliferative capacity [51], and donor-dependent responsiveness [52] likely 
contributing to this apparently stochastic phenomenon.  
The results of this study suggest that post euthanasia-collected tissue samples are a viable 
source of MSCs and behave similarly in vitro to within-donor matched samples collected under 
sedation and general anesthesia. Although allogeneic stem cell therapy faces many clinical 
barriers [53, 54], cadaver tissues serve as a promising source of MSCs. Future research is needed 
to determine any toxicity effects of systemic drugs (such as sedation and anesthetic agents and 
euthanasia solution) on MSCs, define the ideal timing of tissue collection after death, and 
optimize in vitro screening methods for characterizing MSC differentiation potentials from any 
given donor or tissue source.  
 
Conclusions 
 In conclusion, equine adult ADI- and BM-MSCs collected during standing sedation, 
general anesthesia, and post-euthanasia behaved equivalently in vitro in regards to cellular 
viability, proliferation, and osteogenic differentiation capacity outcome measures. Factors such 
as sample-specific osteogenic responsiveness, donor age, initial numbers of viable primary cells, 
and cell seeding density likely impacted in vitro cell behavior and should be considered when 
evaluating donor cell responses. The large degree of inter- and intra-donor variability seen in this 
study further supports optimization of in vitro multi-potential differentiation screening methods 
for selecting viable MSC sources for use in clinical therapeutic applications and cell banking. 
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Figures & Tables 
 




Gender Breed BCS Missing Sample 
1 2 Female intact Quarterhorse 3 Sedation ADI-MSC 
2 8 Female intact Quarterhorse 7 None 
3 8 Female intact Warmblood 6 Euthanasia BM-MSC 
4 9 Male castrated Warmblood 4 Sedation BM-MSC 
 
Table 3.1: Donor horse demographics, including age (years), gender, breed, body condition score 





Figure 3.1: Adipose Tissue Primary Cell Counts 
  
  
Figure 3.1: ADI-MSC primary cell counts expressed as cells per gram of adipose tissue. Results 
are pooled across donors (top) and presented as individual donors (bottom). Asterisks (*) indicate 
a significant effect of donor variability on ADI-MSC primary cell counts (*** p < 0.001). 







Figure 3.2: Bone Marrow Aspirate Primary Cell Counts 
 
  
Figure 3.2: BM-MSC primary cell counts expressed as cells per ml of aspirate and adjusted for 
days to confluence. Results are pooled across donors (top) and presented as individual donors 
(bottom). Asterisks (*) indicate a significant effect of donor variability on BM-MSC primary cell 








Figure 3.3: Population doubling times (PDTs) expressed as days for ADI-MSCs (top) and BM-
MSCs (bottom). “P” = passage number. Asterisks (*) indicate a significant effect of passage on 
PDTs (*** p < 0.001). Deltas (Δ) indicate a significant effect of donor variability on PDTs (Δ p 






Figure 3.4: ADI-MSC Alizarin Red Stain Images 
Horse 3 
ADI-MSC 












   
 
Figure 3.4: Representative 4X magnification images of Day 10 post-osteogenic induction multi-
cellular aggregation and Alizarin Red staining in ADI-MSCs samples from Horse 3. “Cx” = 
control media, “OIM” = osteogenic media, and “BMP-2” = recombinant human bone 
morphogenetic protein 2 supplemented at 100 ng/ml.
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Figure 3.5: Representative 4X magnification images of Day 10 post-osteogenic induction multi-
cellular aggregation and Alizarin Red staining in BM-MSCs samples from Horse 1. “Cx” = 
control media, and “OIM” = osteogenic media.   
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Figure 3.6: ADI-MSC RUNX2 mRNA Expression 
   
Figure 3.6: RUNX2 mRNA expression in ADI-MSCs evaluated at Day 5 (left) and Day 10 (right) post-osteogenic induction. “Cx” = 
control media, “OIM” = osteogenic media, and “BMP-2” = recombinant human bone morphogenetic protein 2 supplemented at 100 
ng/ml. Asterisks (*) indicate a significant effect of culture treatment on RUNX2 expression (**** p < 0.0001, ** p < 0.01). Deltas (∆) 
indicate a significant effect of donor status during collection on RUNX2 expression (∆ p < 0.05). Carets (^) indicate significant post-
hoc test difference from the sedation-collected sample within the culture treatment group (^ p < 0.05). Evaluated with 2-Way 









Figure 3.7: ADI-MSC OSX mRNA Expression 
   
Figure 3.7: OSX mRNA expression in ADI-MSCs evaluated at Day 5 (left) and Day 10 (right) post-osteogenic induction. “Cx” = 
control media, “OIM” = osteogenic media, and “BMP-2” = recombinant human bone morphogenetic protein 2 supplemented at 100 
ng/ml. Evaluated with 2-Way ANOVA, n = 3 – 4, p < 0.05. Y-axes ranges are equivalent to the corresponding BM-MSC OSX mRNA 




Figure 3.8: ADI-MSC ALP mRNA Expression 
 
    
Figure 3.8: ALP mRNA expression in ADI-MSCs evaluated at Day 5 (left) and Day 10 (right) post-osteogenic induction. “Cx” = 
control media, “OIM” = osteogenic media, and “BMP-2” = recombinant human bone morphogenetic protein 2 supplemented at 100 
ng/ml. Asterisks (*) indicate a significant effect of culture treatment on ALP expression (** p < 0.01, * p < 0.05). Evaluated with 2-






Figure 3.9: BM-MSC RUNX2 mRNA Expression 
  
 
Figure 3.9: RUNX2 mRNA expression in BM-MSCs evaluated at Day 5 (left) and Day 10 (right) post-osteogenic induction. “Cx” = 
control media, and “OIM” = osteogenic media. Asterisks (*) indicate a significant effect of culture treatment on RUNX2 expression (* 
p < 0.05). Evaluated with 2-Way ANOVA, n = 3 – 4, p < 0.05. Y-axes ranges are equivalent to the corresponding ADI-MSC RUNX2 






Figure 3.10: BM-MSC OSX mRNA Expression 
 
    
 
Figure 3.10: OSX mRNA expression in BM-MSCs evaluated at Day 5 (left) and Day 10 (right) post-osteogenic induction. “Cx” = 
control media, and “OIM” = osteogenic media. Asterisks (*) indicate a significant effect of culture treatment on OSX expression (* p 
< 0.05). Evaluated with 2-Way ANOVA, n = 3 – 4, p < 0.05. Y-axes ranges are equivalent to the corresponding ADI-MSC OSX 




Figure 3.11: BM-MSC ALP mRNA Expression  
   
 
Figure 3.11: ALP mRNA expression in BM-MSCs evaluated at Day 5 (left) and Day 10 (right) post-osteogenic induction. “Cx” = 
control media, and “OIM” = osteogenic media. Asterisks (*) indicate a significant effect of culture treatment on ALP expression (** p 
< 0.01, * p < 0.05). Evaluated with 2-Way ANOVA, n = 3 – 4, p < 0.05. Y-axes ranges are equivalent to the corresponding ADI-MSC 







Figure 3.12: ADI-MSC ALP Enzymatic Activity 
 
   
Figure 3.12: ALP enzymatic activity in ADI-MSCs evaluated at Day 5 (left) and Day 10 (right) post-osteogenic induction. “Cx” = 
control media, “OIM” = osteogenic media, and “BMP-2” = recombinant human bone morphogenetic protein 2 supplemented at 100 
ng/ml. Evaluated with 2-Way ANOVA, n = 3 – 4, p < 0.05. Y-axes ranges are equivalent to the corresponding BM-MSC ALP 
enzymatic activity figure (Figure 3.13). 
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Figure 3.13: BM-MSC ALP Enzymatic Activity 
  
Figure 3.13: ALP enzymatic activity in BM-MSCs evaluated at Day 5 (top) and Day 10 (bottom) post-osteogenic induction. “Cx” = 
control media and “OIM” = osteogenic media. Asterisks (*) indicate a significant effect of culture treatment on ALP enzymatic 
activity (**** p < 0.0001). Evaluated with 2-Way ANOVA, n = 3 – 4, p < 0.05. Y-axes ranges are equivalent to the corresponding 





Table 3.2: Primers Utilized in the qPCR Reactions 
Gene Target 
(Product Size) 
Primer Sequence & Start Site 





S: 5’ – TGGGGTGAAGGCTAATGAGG – 3’ (463) 






S: 5’ – CCCGGACACAGAGACTTCAT – 3’ (277) 






S: 5’ – GGCTATGCCAATGACTACCC – 3’ (337) 






S: 5’ – CAGACCAGCAGCACTCCATA – 3’ (1135) 





Table 3.2: Sense (S) and antisense (A) sequences for primers utilized in the qPCR reactions, 
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Characterization of the RUNX2 and OSX Regulatory Axis in Equine Mesenchymal Stem 
Cells During In Vitro Osteogenesis 
Abstract 
Osteogenesis is a complex process involving the differentiation of mesenchymal stem 
cell (MSC) precursors into osteoblasts. Two master regulators of osteogenesis are the 
transcription factors runt-related transcription factor 2 (RUNX2) and osterix/SP7 (OSX). In 
developmental models, both RUNX2 and OSX were found to be necessary for skeletogenesis, 
with RUNX2 acting upstream of OSX. MSCs, by definition, are capable of multi-lineage 
differentiation, yet the osteogenic capacity of MSCs from different tissue sources varies 
considerably. Bone marrow-derived MSCs exhibit more potent osteogenic capacity than several 
other putative progenitor populations, including adipose-derived (ADI) MSCs. The purposes of 
this study were to 1) compare baseline and osteogenesis-induced RUNX2 and OSX expression 
levels in equine adult ADI- and BM-MSCs, and 2) determine the impact of OSX over-expression 
on the in vitro osteogenic capacity of ADI-MSCs. The hypotheses were that 1) the relative 
osteogenic capacities of ADI- and BM-MSCs are consistent with resting and inducible RUNX2 
and OSX expression levels, and 2) increasing OSX over-expression in ADI-MSCs would 
improve their osteogenic capacity. Results show that BM-MSCs have significantly higher OSX, 
but not RUNX2, baseline mRNA expression levels compared to ADI-MSCs. Osteogenic 
induction of RUNX2 was similar between cell types, but only BM-MSCs significantly 
upregulated OSX. OSX over-expression in ADI-MSCs did not result in significant improvements 
in osteogenic outcomes. In conclusion, the osteogenic response of ADI- and BM-MSCs may be 
due in part to differences in their RUNX2-OSX response axes, but other factors also have a 
substantial influence on osteogenic capacity. Over-expression of OSX is not sufficient by itself 
for improving osteogenic differentiation. 
 
Introduction 
 Bone formation during embryonic development (skeletogenesis) and fracture repair 
requires specialized cells called osteoblasts that are derived through osteogenesis. Mesenchymal 
stem cells (MSCs) give rise to osteo-chondro progenitor cells that are capable of terminally 
differentiating into chondrocytes or osteoblasts. During osteogenesis, many internal and external 
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cues, such as growth factors, hormones, signaling pathways, and transcription factors, dictate the 
response of the cells to osteogenic stimuli at specific time points throughout the process 
[reviewed in 1]. Osteoprogenitor cells express two main transcription factors: runt-related 
transcription factor 2 (RUNX2), also known as core-binding factor subunit alpha-1, and osterix 
(OSX), also known as transcription factor Sp7. RUNX2 and OSX are considered to be “master 
regulators” of osteogenesis, as gene deletion studies in murine models have categorically 
demonstrated that both RUNX2 [2] and OSX [3] are required for skeletogenesis. Mice lacking 
either gene do not develop a mineralized appendicular skeleton. Further studies illustrated that 
OSX expression is dependent on RUNX2 induction during bone development [reviewed in 4], 
since RUNX2-null mice do not express OSX, while OSX-null mice do express RUNX2.  
 Runt-related transcription factor genes encode for proteins with a common 128-amino 
acid long ‘Runt domain’ located at the N-terminal site, which is responsible for both the binding 
of DNA by the α subunit and hetero-dimerization with the non-DNA binding β subunit 
[reviewed in 5 – 7]. RUNX2 gene expression is transcriptionally regulated by a distal P1 and 
proximal P2 promoter, which results in two mRNA products (Type II and Type I, respectively) 
that differ in the 5’ region with identical 3’ ends [6, 7]. The RUNX2 gene spans approximately 
200 kb and comprises eight exons: exons 2 through 8 encode the ATP binding site, 
glutamine/alanine-rich domain, runt homology domain, a nuclear localization signal, a 
proline/serine/threonine-rich domain, and a nuclear matrix targeting signal [6]. The Type II 
RUNX2 isoform is mainly associated with osteoblasts [8] and originates from an alternative 
translation start codon within exon 1 [9]. RUNX2 gene expression is regulated by multiple 
stimulatory and inhibitory transcription factors [reviewed in 5] and several signaling pathways 
such as transforming growth factor beta (TGF-β) / bone morphogenetic protein (BMP) signaling 
molecules, fibroblast growth factors (FGF), retinoic acid, and glucocorticoids [reviewed in 6]. 
RUNX2 protein primarily interacts with core binding factor beta (CBFβ), which enhances the 
DNA binding affinity of the Runt domain [10]. Downstream targets of RUNX2 include an 
osteoblast-specific element 2 (OSE2) binding element originally identified in the promoter 
region of the gene osteocalcin (OSC) [11]. The most common targets that are important or 
specific to osteoblast differentiation include bone sialoprotein (BSP), collagen type I alpha-1 
(COL1A1), osteocalcin (OSC), and osteopontin (OSP) [reviewed in 5 – 7]. Other osteoblast 
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targets include ameloblastin, collagenase 3 / matrix metalloproteinase 13 (MMP-13), 
osteoprotegrin, and TGF-β type I receptor [reviewed in 6].  
OSX is a zinc finger-containing transcription factor that is a member of the SP family of 
DNA-binding proteins [3]. The OSX gene contains only 2 exons: exon 1 encodes for 7 amino 
acids at the N-terminal region, while exon 2 contains the remaining open reading frame and 3’ 
untranslated region [3]. The OSX protein is approximately 428 amino acids long with a 
molecular mass of around 46 kDa [12]. The DNA binding domain of OSX consists of three 
C2H2-type zinc fingers at the C-terminus, which interact with specificity protein 1 (SP1) and 
Krueppel-like factor 1 (EKLF) consensus sequences and other G/C-rich sequences commonly 
found in promoters [reviewed in 12]. The OSX protein sequence also contains a proline- and 
serine-rich transactivation domain, close to the N-terminus, which is responsible for eliciting an 
inhibitory effect on the Wnt signaling pathway [13]. OSX gene expression is regulated by 
several RUNX2-dependent and -independent pathways [reviewed in 14, 15], and its expression is 
necessary to further differentiation precursor cells into mature, functional osteoblasts [3, 
reviewed in 16]. The upstream regulatory sequence of the OSX promoter contains response 
elements for distal-less homeobox 5 (DLX-5), RUNX2, SRY-like box 9 transcription factor 
(SOX-9), SP1, and vitamin D response element (VDRE) [15]. OSX is directly induced by 
RUNX2, DLX-5, the BMP, mitogen-activated protein kinase (MAPK), and insulin-like growth 
factor 1 (IGF-1) signaling pathways, and the endoplasmic reticulum (ER) stress pathway through 
inositol-requiring enzyme 1 alpha (IRE1a) / x-box binding protein 1 (XBP1) [reviewed in 15 – 
18]. OSX can also regulate its own expression through positive feedback on its promoter [19]. 
Downstream targets of OSX that are partially or fully dependent on its expression and induction 
include alkaline phosphatase (ALP), BSP, COL1A1, OSC, osteonectin (OSN), and OSP [3, 16].  
MSCs from adult tissues are a promising source of cell therapy for use in regenerative 
medicine applications. In veterinary medicine, MSCs are typically used in horses for treatment of 
orthopedic injuries or degenerative conditions and are commonly harvested via bone marrow 
(BM) aspiration or adipose (ADI) tissue collection [20]. There is an interest in optimizing MSCs 
for use in bone repair and regeneration [reviewed in 21], especially in species like the horse that 
often have increased morbidity and mortality from fracture [22]. The purpose of this study was to 
compare the RUNX2-OSX response axis in equine adult ADI- and BM-MSCs to determine its 
impact on their differing osteogenic capacities. The experiments were designed to first compare 
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baseline and osteogenesis-induced RUNX2 and OSX expression levels, and then determine the 
effect of adenovirus-directed OSX over-expression on the osteogenic capacity of ADI-MSCs. 
The hypotheses were that ADI-MSCs had lower baseline and induced RUNX2 and OSX 
expression levels than BM-MSCs, and therefore increasing expression of OSX would improve 
the osteogenic capacity of ADI-MSCs.  
 
Materials & Methods 
Research Animals & Cell Samples 
All procedures were approved by the University of Illinois Institutional Animal Care and 
Use committee (IACUC). Healthy, adult horses between the ages of 2 – 10 years old were 
donated to the Veterinary Teaching Hospital for teaching and/or research purposes. Adipose 
tissue and bone marrow aspirates were collected and MSCs were isolated as outlined in Chapter 
3. For the experiments outlined in this study, 4 – 6 different cell samples were used immediately 
after collection and isolation or were cryo-stored until required. 
 
Cell Culture & Expansion 
 Culture procedures are similar as those outlined in Chapter 3. Briefly, passage 2 – 3 cells 
were seeded in 100-mm dishes at approximately 5,000 cells/cm
2
 in growth media [1X 
Dulbecco’s modified Eagle’s medium (DMEM), 10% fetal bovine serum (FBS), 100 U/ml 
penicillin, and 100 streptomycin μg/ml (1% P/S)]. Passage 2 – 3 cells were trypsinized at near-
confluence and transferred to osteogenesis and adenovirus experiments. Cells were counted 
using the Trypan Blue exclusion method, as outlined in Chapter 3.  
 
In Vitro Osteogenesis 
Third passage (P3) MSCs were seeded at 2,000 cells/cm
2
 in cell culture plates and 
maintained in growth media until approximately 50% confluence was reached. Control (Cx) 
cultures remained in growth media, while osteogenic cultures were be maintained with 
osteogenic induction media (OIM), which consisted of growth media base supplemented with 50 
μg/ml L-Ascorbic Acid Phosphate Magnesium Salt n-Hydrate (Wako, Japan), 10 mM β-
Glycerophospate (Sigma-Aldrich), and 100 nM Dexamethasone (Sigma-Aldrich). Cultures were 
maintained for up to 7 days, during which media was replaced every 2 – 3 days and 
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representative digital pictures were taken via light microscopy. Cells were collected for RNA 
isolation at multiple time points after osteogenic induction. 
 
RNA Isolation & Quantification, Reverse Transcription, and Quantitative Real-Time PCR 
 All procedures are outlined in detail in Chapter 3. Total RNA was isolated using the 
TRIzol® reagent protocol and quantified using a NanoDrop 2000 spectrophotometer. RNA was 
reverse transcribed into cDNA using the SuperScript
TM
 IV First-Strand Synthesis System kit 
protocol. Quantitative real-time PCR (qPCR) was performed using the iQ
TM
 SYBR® Green 
Supermix and iCycler iQ
TM
 thermocycler (BIO-RAD) protocol outlined in Chapter 3. Primers 
utilized in the qPCR reactions are listed in Table 4.1. Data were analyzed using the 2
-ΔΔCT 
method by normalizing to the reference gene, EF1α, and an early time point control sample. 
Comparisons between ADI- and BM-MSCs were made by normalizing all data to BM control 
samples, since this has served as a reference or “positive” control in previous studies.  
 
Adenovirus Optimization  
Adenoviral multiplicities of infection (MOI) were optimized in a dose-response 
observational trial. ADI-MSC samples were infected at 24 doses between 0.5 – 1000 MOI, 
maintained in either control (Cx) or osteogenic (OIM) media, and observed daily for 14 days to 
monitor cell viability and survival.  
 
OSX Adenovirus Infection 
ADI-MSC samples maintained in Cx and osteogenic media were infected with an 
OSX/SP7 adenovirus (VectorBiolabs ADV-224052) to assess the impact of increased OSX 
expression on induction of downstream osteoprogenitor marker target genes and osteogenesis. 
The OSX adenovirus (Ad-OSX) contained a cDNA clone of a Homo sapiens OSX/SP7 mRNA 
(GenBank: BC113613.1) under control of a CMV promoter and co-expressing an enhanced 
green fluorescent protein (eGFP) tag. Comparisons between the adenovirus OSX transcript 
sequence and predicted Equus caballus mRNA sequences using BLAST
®
 (NCBI) resulted in 
92% mRNA homology and up to 98% protein sequence homology. An eGFP vehicle control 
adenovirus (Ad-GFP) was also used to determine any effect of adenovirus infection on cells. The 
eGFP product of both adenoviruses allowed for tracking of infection efficacy via fluorescent 
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microscopy. Based on adenovirus optimization results, both a mid-range MOI of 20 and high-
range MOI of 100 were used to evaluate a dose-response effect of OSX over-expression on 
downstream gene targets and osteogenesis assay outcomes. Samples were maintained in Cx and 
osteogenic media and collected at days 4 and 7 post-infection for RNA isolation, ALP 
bioactivity, and Alizarin Red staining.  
 
Osteogenesis Assays 
In addition to osteogenic gene expression via RT-qPCR described above, Alizarin Red 
mineralized matrix staining and ALP bioactivity assays were performed as outlined in Chapter 3.  
 
Statistical Analyses 
All data were analyzed using GraphPad Prism (GraphPad Software, INC) and expressed 
as mean + the standard error of the mean (SEM). Data were evaluated for normality using the 
Kolmogorov-Smirnov, D’Agostino and Pearson, and Shapiro-Wilk normality tests, where 
appropriate. Normally distributed data was analyzed using the tests mentioned below for each 
comparison. If normality could not be determined due to small sample size or data did not pass 
any of the normality tests, a corresponding non-parametric test was also performed. Statistical 
significant was assigned at p < 0.05. Sample sizes were n = 4 horses per cell type for baseline 
and temporal gene expression, and n = 6 horses for OSX over-expression in ADI-MSCs data.  
Differences between ADI- and BM-MSC baseline mRNA expression of RUNX2 and 
OSX were evaluated using 2-Way Analysis of Variance (ANOVA). Comparisons between the 
two cell types were performed by normalizing to BM Day 0 samples. Bonferonni post-hoc 
testing was performed to compares between cell types at each collection time point.  
Temporal changes in mRNA expression of RUNX2 and OSX in control versus 
osteogenic media within each cell type over time were evaluated using 2-Way ANOVA. 
Bonferonni post-hoc testing was performed to compare control and osteogenic media values at 
each time point. Comparison between ADI- and BM-MSCs temporal changes in mRNA 
expression of RUNX2 and OSX in osteogenic media was evaluated at each time point using 2-
Way ANOVA by normalizing to BM Day 2 control samples. Bonferonni post-hoc testing was 
performed to compare ADI- and BM-MSC osteogenic responses at each time point.  
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The effect of OSX over-expression on mRNA expression and ALP activity was evaluated 
using 2-Way ANOVA. Bonferonni post-hoc testing was performed to determine significant 
comparisons between OSX adenovirus and control treatments at each time point. The effect of 
osteogenic media compared to control media for each outcome measure was evaluated in a 
separate 2-Way ANOVA at each time point. 
 
Results 
Baseline RUNX2 & OSX mRNA Expression 
 RUNX2 mRNA levels in basal/resting MSC cultures did not differ between ADI- and 
BM-MSCs at any of the time point evaluated (Figure 4.1). RUNX2 expression overall was not 
affected by cell type or time in culture. 
OSX mRNA levels in basal/resting MSC cultures were significantly higher (p = 0.0037) 
in BM- compared to ADI-MSCs across all time points evaluated (Figure 4.1). Post-hoc testing 
found a statistically significant increase in OSX levels in BM- compared to ADI-MSCs at Day 2 
(p < 0.01). OSX expression was not affected by time in culture. 
 In summary, baseline OSX, but not RUNX2, mRNA expression levels are significantly 
higher overall in BM-MSCs compared to ADI-MSCs.  
 
Osteogenesis-Induced RUNX2 & OSX mRNA Expression 
 RUNX2 mRNA expression levels (Figure 4.2 (A)) were significantly increased by 
osteogenic media over all time points evaluated in both ADI- (p = 0.0013) and BM- (p = 0.0020) 
MSCs. Post-hoc testing found a statistically significant increase in RUNX2 expression in 
osteogenic media compared to control media in BM-MSCs at the Day 7 time point (p < 0.05). 
 OSX mRNA expression levels (Figure 4.2 (A)) were significantly increased in 
osteogenic media compared to control media in BM-MSCs at the Day 7 time point (p < 0.05). 
However, there was no induction of OSX in ADI-MSC cultures.  
There was a significant difference between cell types (Figure 4.2 (B)) in the induction of 
both RUNX2 (p = 0.0180) and OSX (p = 0.0348). Further, OSX expression was significantly 
increased in osteogenic BM- compared to ADI-MSC cultures at the Day 7 time point (p < 0.01). 
 In summary, both ADI- and BM-MSCs significantly up-regulated RUNX2 mRNA 
expression in response to osteogenic media overall, but only BM-MSCs showed a significant 
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increase in OSX mRNA expression in response to osteogenic media by Day 7. Comparison 
between the two cell types showed that BM-MSCs had significantly higher induced levels of 
RUNX2 and OSX overall compared to ADI-MSCs, with significantly higher OSX expression 
seen in Day 7 BM- compared to ADI-MSC osteogenic samples. 
 
Adenoviral Vector Optimization 
GFP was detectable via fluorescence microscopy by day 2 post-infection at the higher 
doses tested, with intensity peaking by Day 7 and then gradually decreasing over time (images 
not shown). In Cx media, cells survived up to 14 days at the highest MOI tested, 1000. However, 
cell survival in OIM was impaired by adenoviral MOIs greater than MOI 100 past Day 7.  
 
Effect of OSX Over-Expression on ADI-MSCs in Control Conditions 
 Cell culture, GFP fluorescence intensity, and Alizarin Red staining images for ADI-
MSCs infected with OSX adenovirus (Ad-OSX) at MOIs of 20 and 100 in control media are 
represented in Figure 4.3. At Day 4 post-infection, the higher Ad-OSX dose slightly increased 
cellular aggregation compared to the lower MOI and control cultures. However, this effect was 
not apparent at Day 7. GFP fluorescence levels reflected the adenovirus infective dose and were 
equivalent between Ad-GFP and Ad-OSX MOI 100 cultures. Alizarin Red staining was negative 
in control cultures at both the Day 4 and Day 7 time points. 
 ALP mRNA expression and enzymatic activity are represented in Figure 4.4. ALP 
mRNA expression transiently increased in the Ad-OSX treated groups compared to controls in a 
dose-dependent manner, but the magnitude was not considered significant. ALP expression was 
significantly decreased at the Day 7 time point compared to the Day 4 time point (p = 0.0414). 
ALP enzymatic activity levels were not significantly affected by Ad-OSX treatment or time post-
infection in control cultures.  
 Downstream osteoprogenitor markers mRNA expression for bone sialoprotein (BSP), 
collagen type I A1 (COL1A1), osteocalcin (OSC), osteomodulin (OSM), osteonectin (OSN), and 
osteopontin (OSP) are represented in Figure 4.5. BSP was the only gene significantly increased 
by Ad-OSX treatment (p = 0.0487), but the effect was not dose-dependent. None of the genes 
were significantly affected by time post-infection. Post-hoc testing did not find a significant 
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increase in gene expression with either Ad-OSX dose compared to controls at either time point 
for any of the genes evaluated.  
 In summary, OSX over-expression in ADI-MSCs under control conditions resulted in a 
slight increase in cellular aggregation at Day 4 in the higher dose tested, a non-significant dose-
dependent increase in ALP mRNA expression at Day 4, and a significant increase in BSP mRNA 
expression at both time points compared to controls.  
 
Effect of OSX Over-Expression on ADI-MSCs in Osteogenic Conditions 
Cell culture, GFP fluorescence intensity, and Alizarin Red staining images for ADI-
MSCs infected with OSX adenovirus (Ad-OSX) at MOIs of 20 and 100 in osteogenic media are 
represented in Figure 4.6. At both Day 4 and Day 7 post-infection, there was no apparent 
increase in cellular aggregation in Ad-OSX treated cultures compared to control cultures. GFP 
fluorescence levels reflected the adenoviral infective dose and were equivalent between Ad-GFP 
and Ad-OSX MOI 100 cultures. Alizarin Red staining was negative in osteogenic cultures at 
both the Day 4 and Day 7 time points. Alizarin Red staining was positive in a single experiment 
extended to Day 14, but there was no apparent difference between Ad-GFP and Ad-OSX 
infected cultures regarding Alizarin Red intensity (data not shown).  
 ALP mRNA expression and enzymatic activity are represented in Figure 4.7. ALP 
expression increased slightly in the Ad-OSX MOI 100 group compared to controls, but the 
difference was not significant. ALP expression overall was significantly increased at the Day 7 
time point compared to the Day 4 time point (p = 0.0271). ALP activity levels were not 
significantly affected by Ad-OSX treatment or time post-infection. However, Day 7 values were 
generally higher than Day 4 levels. ALP mRNA expression, but not ALP enzymatic activity, was 
significantly increased in osteogenic compared to control media samples (p = 0.0252). 
 Downstream osteoprogenitor markers mRNA expression for bone sialoprotein (BSP), 
collagen type I A1 (COL1A1), osteocalcin (OSC), osteomodulin (OSM), osteonectin (OSN), and 
osteopontin (OSP) are represented in Figure 4.8. None of the genes were significantly affected 
by Ad-OSX treatment. COL1A1 was significantly decreased at Day 7 compared to Day 4 (p < 
0.0001). Osteogenic media resulted in a significant increase in OSM (p = 0.0368), significant 
decrease in COL1A1 (p < 0.0001) and OSP (p = 0.0036), and did not significantly affect BSP, 
OSC, and OSN compared to control media. 
95 
 
 In summary, OSX over-expression in ADI-MSCs under osteogenic conditions did not 
affect cellular aggregation or Alizarin Red staining, resulted in a non-significant dose-dependent 
increase in ALP mRNA expression at both Day 4 and Day 7, and did not consistently affect any 
of the downstream osteoprogenitor marker genes at either time point compared to controls 
 
Discussion 
 This study sought to characterize differences in the RUNX2-OSX regulatory axis in 
equine adult adipose (ADI) and bone marrow (BM) derived mesenchymal stem cells (MSCs), to 
determine whether differences in expression profiles influenced the osteogenic capacity of these 
cells. The goals were to first evaluate baseline and osteogenesis-induced expression levels of 
each, and then determine whether OSX over-expression improved osteogenic differentiation 
outcomes in ADI-MSCs. The hypotheses were that ADI-MSCs had lower baseline and induced 
RUNX2 and OSX expression levels than BM-MSCs, and therefore increasing expression of 
OSX would improve their osteogenic capacity. Results suggest that there are consistent 
differences in OSX, but not RUNX2, expression between the two cell types, but compensating 
for this difference in ADI-MSCs by directly over-expressing OSX was not sufficient to improve 
their osteogenic capacity to a level comparable to BM-MSCs. 
 Several studies have compared the osteogenic potential of MSCs from different tissue 
sources, in both animal models and humans. BM-MSCs have been found to have superior 
osteogenic capacity to ADI-MSCs in humans [23], rats [24, 25], dogs [26, 27], goats [28], and 
horses [29, 30]. Other comparative studies performed in horses have found that MSCs from 
multiple sources are capable of osteogenic differentiation [31, 32], but these studies did not 
evaluate differences in osteogenic gene expression profiles. RUNX2 and OSX are essential 
master transcriptional regulators for osteogenesis, and this study showed that there is a difference 
in the baseline ‘set point’ of OSX: BM-MSCs have significantly higher resting levels than ADI-
MSCs. OSX is also a downstream target of RUNX2, and results here suggest that BM-MSCs 
induced OSX more than ADI-MSCs in response to osteogenic induction. In summary, it is likely 
that the differential osteogenic capacities of ADI- and BM-MSCs are due, in part, to their 
difference in OSX expression profiles and responses.  
 There have been many biological and genetic engineering-based approaches proposed to 
improve MSC use in bone repair/regeneration [reviewed in 33 – 36]. In this study, adenoviruses 
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were used to over-express OSX and evaluate the impact on downstream osteogenic gene targets 
and osteogenesis. Adenoviruses are highly efficient at delivering DNA to cells, are not 
dependent on cell replication for successful infection, and typically do not integrate with the host 
genome. The adenovirus infection process involves cells binding to viral proteins through 
various surface receptors for adenoviruses and αv integrins, which are widely distributed among 
different cell types [37]. Adenoviruses typically remain in the nucleus of infected cells as an 
episome, which will gradually degrade as cells divide [38]. The observation of decreasing GFP 
fluorescence at later time points post-infection supports this, which suggests that any potential 
benefit of adenovirus-directed gene over-expression may be short-lived. This could also explain 
why in the OSX over-expression experiments, the increase in OSX expression around the same 
time as osteogenic induction may not have been sufficient to improve osteogenesis since OSX is 
required for mid-stage osteoblast differentiation [reviewed in 12, 16]. In fact, sustained OSX 
over-expression may actually inhibit terminal osteoblastogenesis [19]. 
 The difference in baseline and inducible OSX expression between ADI- and BM-MSCs 
may be due to several upstream pathways. Both RUNX2-dependent and -independent pathways 
regulate OSX expression, notably Bone Morphogenetic Protein (BMP) signaling [14 – 18]. Other 
factors involved in OSX regulation include MAPK-p38/Erk1-2 and Insulin-like Growth Factor 1 
signaling, and inhibitory influences by Tumor Necrosis Factor α (TNFα) and p53 [reviewed in 
16]. A multitude of epigenetic-level events have been shown to regulate OSX and its target 
genes, such as microRNAs [39], DNA methylation [40], and histone demethylases [41]. Further 
studies should evaluate difference in the epigenetic landscape in ADI- and BM-MSCs pertaining 
to osteogenic regulatory genes, especially with recent advances in epigenetic screening 
techniques and the potential for using epigenetic approaches in MSC-based bone regeneration 
[reviewed in 42, 43].  
 OSX over-expression was insufficient for improving ADI-MSC osteogenesis. Several 
studies have evaluated the effects of RUNX2 or OSX over-expression on osteogenesis. In murine 
bone marrow MSCs, RUNX2 over-expression enhanced the osteogenic activity both in vitro and 
in vivo [44]. However, RUNX2 over-expression impaired osteoblastogenesis at later stages and 
lead to osteopenia in murine models [45], and RUNX2 can contribute to development of 
osteosarcoma [reviewed in 46], thus emphasizing the temporal importance of RUNX2 activities 
[47]. OSX over-expression induces osteogenic differentiation in vitro in murine embryonic stem 
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cells [48] and murine bone-marrow derived MSCs [49]. OSX also stimulates proliferation in 
murine bone-marrow derived MSCs [49] and NIH-3T3 fibroblasts [50]. However, in NIH-3T3 
fibroblast cells, OSX over-expression was insufficient to induce osteoblastic differentiation [50]. 
It is evident that even though RUNX2 and OSX are considered “master regulators” of 
osteogenesis, their expression profiles and activity are tightly regulated and timed during 
osteoblast differentiation [1, 5, 6, 16]. Given that over-expression of either transcription factor by 
itself is not sufficient for complete osteoblast differentiation, it is likely that a combinatorial 
approach of molecular targets would be most effective in enhancing the osteogenic capacity of 
MSCs. For example, it has been proposed that the use recombinant BMP with genetically-
engineered cells capable of expressing RUNX2 and OSX could achieve complete and robust 
osteogenesis [reviewed in 34].  
 
Conclusion 
 Equine adult BM-MSCs were found to have higher baseline and inducible gene 
expression levels of OSX, but not RUNX2, compared to ADI-MSCs. These findings may 
provide a partial explanation as to why BM-MSCs show superior osteogenic capacity to ADI-
MSCs. Over-expression of OSX in ADI-MSCs slightly increased expression of the downstream 
genes ALP and BSP, but other osteogenic differentiation outcomes such as cellular aggregation, 
Alizarin Red mineralized matrix staining, and ALP enzymatic activity were not improved. Over-
expression of OSX alone is not sufficient for improving osteogenic differentiation capacity of 
ADI-MSCs out to Day 7. A preliminary study using sustained OSX over-expression out to Day 
14 also did not significantly improve osteogenic outcomes. Further studies should focus on 
determining the precise timing of inducible RUNX2 or OSX over-expression to maximize their 
benefit during osteogenesis, or combinatorial approaches that also enhance the BMP signaling 




Figures & Table 
 
Figure 4.1: Baseline RUNX2 & OSX mRNA Expression 
 
 
Figure 4.1: Baseline/resting mRNA expression levels of RUNX2 (top) and OSX (bottom) in 
adipose-derived (ADI) and bone marrow-derived (BM) MSCs. Asterisks (*) indicate a 
significant effect of cell type on mRNA expression (** p < 0.01). Carets (^) indicate significant 
post-hoc test differences between cell types at a given time point (^^ p < 0.01). Evaluated with 









Figure 4.2 (A): Osteogenesis-induced mRNA expression levels of RUNX2 and OSX in ADI- 
(top) and BM- (bottom) MSCs. “Cx” = control media, and “OIM” = osteogenic media. Asterisks 
(*) indicate a significant effect of culture treatment on mRNA expression (** p < 0.01). Carets 
(^) indicate significant post-hoc test differences between culture treatments at a given time point 
(^ p < 0.05, ^^ p < 0.01). Evaluated with 2-Way ANOVA, n = 4, p < 0.05. 
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Figure 4.2 (B): Comparative Osteogenic Media Induction of 




Figure 4.2 (B): Comparative osteogenesis-induced mRNA expression levels of RUNX2 and 
OSX in ADI- and BM-MSCs pooled for Day 2 (D2), Day 4 (D4), and Day 7 (D7). “Cx” = 
control media, and “OIM” = osteogenic media. Asterisks (*) indicate a significant effect of cell 
type on mRNA expression (* p < 0.05). Carets (^) indicate significant post-hoc test differences 








Figure 4.3: Effect of OSX Over-Expression on ADI-MSCs in Control Media: 
Representative Culture Images 
 
Media & Time Point No Treatment + Ad-GFP (MOI 100) + Ad-OSX (MOI 20) + Ad-OSX (MOI 100) 
Cx – Day 4 
Alizarin Red Stain 
4X Magnification 
    
Cx – Day 4 
GFP Fluorescence 
4X Magnification 
    
Cx – Day 7 
Alizarin Red Stain 
4X Magnification 
    
Cx – Day 7 
GFP Fluorescence 
4X Magnification 
    
 
Figure 4.3: Representative 4X magnification images of Day 4 and Day 7 post-adenovirus infection multi-cellular aggregation and 
Alizarin Red staining in ADI-MSCs maintained in control (Cx) media. “Ad-OSX” = Osterix adenovirus, “Ad-GFP” = enhanced GFP 




Figure 4.4: Effect of OSX Over-Expression on ADI-MSCs in Control Media: 




Figure 4.4: ALP mRNA expression (left) and enzymatic activity (right) in ADI-MSC samples 
collected at Day 4 and Day 7 post-adenovirus infection and maintained in control (Cx) media. 
“Ad-OSX” = Osterix adenovirus, “Ad-GFP” = enhanced GFP vehicle control adenovirus, and 
“MOI” = multiplicity of infection.  Asterisks (*) indicate a significant effect of time post-




Figure 4.5: Effect of OSX Over-Expression on ADI-MSCs in Control Media: 





Figure 4.5: Downstream osteoprogenitor marker genes mRNA expression of bone sialoprotein 
(BSP), collagen type I A1 (COL1A1), osteocalcin (OSC), and osteomodulin (OSM) in ADI-
MSC samples collected at Day 4 and Day 7 post-adenovirus infection and maintained in control 
(Cx) media. “Ad-OSX” = Osterix adenovirus, “Ad-GFP” = enhanced GFP vehicle control 
adenovirus, and “MOI” = multiplicity of infection.  Asterisks (*) indicate a significant effect of 
culture treatment (* p < 0.05). Evaluated with 2-Way ANOVA, n = 6, p < 0.05. 
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Figure 4.5: Downstream osteoprogenitor marker genes mRNA expression of osteonectin (OSN) 
and osteopontin (OSP) in ADI-MSC samples collected at Day 4 and Day 7 post-adenovirus 
infection and maintained in control (Cx) media. “Ad-OSX” = Osterix adenovirus, “Ad-GFP” = 
enhanced GFP vehicle control adenovirus, and “MOI” = multiplicity of infection. Evaluated with 
2-Way ANOVA, n = 6, p < 0.05.  
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Figure 4.6: Effect of OSX Over-Expression on ADI-MSCs in Osteogenic Media: 
Representative Culture Images 
 
Media & Time Point No Treatment + Ad-GFP (MOI 100) + Ad-OSX (MOI 20) + Ad-OSX (MOI 100) 
OIM – Day 4 
Alizarin Red Stain 
4X Magnification 
    
OIM – Day 4 
GFP Fluorescence 
4X Magnification 
    
OIM – Day 7 
Alizarin Red Stain 
4X Magnification 
    
OIM – Day 7 
GFP Fluorescence 
4X Magnification 
    
 
Figure 4.6: Representative 4X magnification images of Day 4 and Day 7 post-adenovirus infection multi-cellular aggregation and 
Alizarin Red staining in ADI-MSCs maintained in osteogenic (OIM) media. “Ad-OSX” = Osterix adenovirus, “Ad-GFP” = enhanced 
GFP vehicle control adenovirus, and “MOI” = multiplicity of infection.
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Figure 4.7: Effect of OSX Over-Expression on ADI-MSCs in Osteogenic Media: 





Figure 4.7: ALP mRNA expression (left) and enzymatic activity (right) in ADI-MSC samples 
collected at Day 4 and Day 7 post-adenovirus infection and maintained in osteogenic (OIM) 
media. “Ad-OSX” = Osterix adenovirus, “Ad-GFP” = enhanced GFP vehicle control adenovirus, 
and “MOI” = multiplicity of infection.  Asterisks (*) indicate a significant effect of time post-








Figure 4.8: Effect of OSX Over-Expression on ADI-MSCs in Osteogenic Media: 





Figure 4.8: Downstream osteoprogenitor marker genes mRNA expression of bone sialoprotein 
(BSP), collagen type I A1 (COL1A1), osteocalcin (OSC), and osteomodulin (OSM) in ADI-
MSC samples collected at Day 4 and Day 7 post-adenovirus infection and maintained in 
osteogenic (OIM) media. “Ad-OSX” = Osterix adenovirus, “Ad-GFP” = enhanced GFP vehicle 
control adenovirus, and “MOI” = multiplicity of infection.  Asterisks (*) indicate a significant 
effect of culture treatment (**** p < 0.0001). Evaluated with 2-Way ANOVA, n = 6, p < 0.05. 




Continued from previous page 
 
 
Figure 4.8: Downstream osteoprogenitor marker genes mRNA expression of osteonectin (OSN) 
and osteopontin (OSP) in ADI-MSC samples collected at Day 4 and Day 7 post-adenovirus 
infection and maintained in osteogenic (OIM) media. “Ad-OSX” = Osterix adenovirus, “Ad-
GFP” = enhanced GFP vehicle control adenovirus, and “MOI” = multiplicity of infection. 
Evaluated with 2-Way ANOVA, n = 6, p < 0.05.  
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Primer Sequence & Start Site 





S: 5’ – TGGGGTGAAGGCTAATGAGG – 3’ (463) 






S: 5’ – AGAACACCACCCTGTCTACG – 3’ (418) 






S: 5’ – AGCCAGCAGATCGAGAACAT – 3’ (3834) 






S: 5’ – CCCGGACACAGAGACTTCAT – 3’ (277) 






S: 5’ – CGGTACCTGGATCATTGGC – 3’ (151) 






S: 5’ – TACATCCGTGTGGACCAAAA – 3’ (1000) 






S: 5’ – AACCTTCTGACCGAGAAGCA – 3’ (591) 






S: 5’ – GCCCTTCCAGTTAATCAGGC – 3’  (170) 






S: 5’ – GGCTATGCCAATGACTACCC – 3’ (337) 






S: 5’ – CAGACCAGCAGCACTCCATA – 3’ (1135) 





Table 4.1: Sense (S) and antisense (A) sequences for primers utilized in the qPCR reactions, 
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The Role of Bone Morphogenetic Protein Activity in Equine  
Mesenchymal Stem Cell In Vitro Osteogenesis 
Abstract 
Stem cell therapies primarily utilize cells from bone marrow (BM) and adipose tissue 
(ADI). Although adipose-derived stem cells are easily accessible, the biological activities and 
responses of ADI cells are less robust than those of BM cells. BMP ligands are potent osteo-
stimulants, both developmentally and in clinical applications. The following study addressed the 
hypothesis that the differential osteogenic capacity of BM-MSC and ADI-MSCs cells is a 
consequence of differences in BMP ligand expression and/or induction. Bone marrow aspirates 
and adipose cells collected from the sternebrae and subcutaneous fat depots, respectively, were 
seeded at low density and expanded through two passages. Third passage cells were transferred 
to control or osteogenic cultures for up to 10 days. Basal osteogenic BMP ligand expression was 
determined in undifferentiated BM- and ADI-MSCs, and induced BMP ligand expression was 
measured after transfer to osteogenic medium. Under basal conditions, both BMP-2 and -4 
ligand expression was consistently 4 – 7 times higher in BM cells than in ADI cells. In contrast, 
there was little change in expression of either BMP ligand in ADI cells maintained in osteogenic 
medium. The effect of BMP signaling on in vitro osteogenesis was assessed by monitoring 
multi-cellular aggregation and mineralized matrix formation detected by Alizarin Red staining, 
qPCR analysis of osteogenic genes runt-related transcription factor 2 (RUNX2), osterix (OSX), 
and alkaline phosphatase (ALP), and ALP enzymatic activity as measured by an assay. 
Antagonism of endogenous BMP signaling in BM-MSCs inhibited osteogenesis, while 
exogenous BMP-2 administration in ADI-MSCs significantly increased cell aggregation, matrix 
mineralization, and Osterix (but not RUNX2) expression. These findings support the hypothesis 
that the differential osteogenic capacity of BM-MSC and ADI-MSCs cells is a consequence of 
differences in BMP ligand expression and/or induction. However, given that exogenous BMP-2 
administration was not sufficient to confer a ‘bone marrow MSC’ osteogenic capacity in ADI-
MSCs, other factors are clearly active in this process. Accepting the abundance of adipose tissue 
in most human patients and the comparative ease of adipose tissue collection, exogenous BMP 





In recent decades, mesenchymal stem cell (MSC) therapies have become increasingly 
prominent in the treatment of musculoskeletal conditions, in both people and veterinary species. 
The utility of MSCs for therapeutic applications is based on their capacity for extensive 
proliferation, supporting the generation of large numbers of cells from small number of 
progenitors, their ability to differentiate along several mesenchymal lineages, and their immuno-
modulatory and other trophic effects on host cells [1, 2]. Routinely, the differentiation capacity 
of putative MSC populations is assessed through in vitro tri-lineage differentiation along 
chondrogenic, adipogenic, and osteogenic lineages [3]. The standard assay for in vitro 
osteogenesis is exceptional in that no extrinsic growth factors are required to stimulate robust 
osteogenesis in competent cell populations. Supplementing medium with ascorbic acid, beta 
glycerophosphate, and dexamethasone is sufficient to induce the osteogenic phenotype [4, 5]. 
Bone Morphogenetic Proteins (BMPs) were originally identified as an activity within 
demineralized bone matrix that stimulates mineralization of soft tissue [6]. Since then, 
approximately twenty BMP ligands have been identified, and their importance in the 
development and homeostasis of the skeleton is well established [7]. Although there is 
considerable redundancy in skeletal BMP signaling activity, murine models have clearly 
demonstrated a ‘critical mass’ requirement for BMP signaling in skeletal development, postnatal 
growth, and fracture repair [8 – 10]. Two ligands, BMP-2 and -7, have been commercially 
developed for orthopedic use in spinal fusion and non-union procedures [11 – 13]. 
In equine practice, stem cell therapies primarily utilize progenitor populations isolated 
from bone marrow (BM) and adipose tissue (ADI) [3]. Although adipose-derived stem cells offer 
a very large and easily accessible resource, the biological activities and responses of ADI cells 
are less robust than those of BM cells in many experimental contexts [14 – 16]. This is 
particularly evident in comparative in vitro osteogenesis assessments [17 – 24]. Given the potent 
osteogenic activity of BMPs and the ability of BM-MSCs, but not ADI-MSCs, to undergo 
osteogenic differentiation in standard osteogenic medium, we addressed the hypothesis that the 
differential osteogenic capacity of BM-MSC and ADI-MSCs cells is a consequence of 
differences in BMP ligand expression and/or induction.  
To test this hypothesis, the following four questions were addressed: 
1. Is basal osteo-chondral BMP expression equivalent in BM and ADI cells? 
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2. Is BMP ligand induction under osteogenic conditions equivalent in BM and ADI cells? 
3. Does BMP signaling blockade inhibit BM-MSC osteogenesis? 
4. Does exogenous BMP-2 ligand supplementation stimulate ADI-MSC osteogenesis? 
 
Materials & Methods 
Bone Marrow and Adipose Tissue Collection 
Bone marrow aspirates and adipose tissue samples were collected from healthy adult 
horses, under approval by the University of Illinois Institutional Animal Care and Use committee 
(IACUC). Donor horses were sedated prior to collections, and collection sites were aseptically 
prepared and desensitized with local anesthetic. Bone marrow aspirates were collected from the 
5th or 6th sternebrae, using a ventral midline approach and a Jamshidi biopsy needle. Adipose 
tissue was collected from the fat depot adjacent the tail head, following local desensitization of 
the biopsy site [25]. Chapter 3 contains more details on sample collection and processing. 
 
MSC Isolation and Culture 
Both the bone marrow aspirates and adipose cells isolated by collagenase digestion were 
seeded at low density in DMEM + 10% FBS, supplemented with antibiotics and expanded 
through two passages. Assessment of BMP ligand expression, BMP inhibition in BM-MSC 
cultures, and exogenous recombinant human BMP-2 (Gemini Bioscience) supplementation in 
ADI-MSC osteogenic cultures was carried out using third passage (P3) cells. Cells were 
maintained in control (as above) or transferred to osteogenic induction medium (1X DMEM + 
10% FBS supplemented with ascorbic acid, beta glycerophosphate, and dexamethasone), for up 
to 10 days. Chapter 3 contains more details regarding osteogenesis induction media and assays. 
To assess the effects of BMP signaling blockade on BM-MSC osteogenesis, osteogenic 
medium was supplemented with the extracellular BMP inhibitor recombinant Noggin protein (10 
– 1000 ng/ml; R&D Biosystems), and small molecule BMP receptor kinase inhibitors DMH-1 
(10 – 500 nM; Calbiochem) and K-02288 (10 – 500nM; TOCRIS). 
A panel of phenotypic assays was used to assess differential BMP expression and 
induction, the effect of BMP inhibition on BM-MSC osteogenesis, and exogenous BMP 





Expression of osteogenic BMP-2, -4, -6, and -7 ligand transcripts and of osteogenic genes 
[26 – 30] was assessed by quantitative PCR (qPCR). Induction of alkaline phosphatase (ALP) 
activity was measured by a commercial enzymatic assay, and generation of mineralized matrix 
was monitored by Alizarin Red staining [30]. See Chapter 3 for more details on methodology.  
 
MSC Aggregation 
The formation of prominent multi-cellular aggregates is a characteristic early feature of 
osteogenic differentiation in competent cell populations. To monitor the effects of BMP 
inhibition on this process in BM-MSC cultures, aggregates in ten random low power (10X 
objective) microscopic fields were counted on days 3, 7, and 10 after transfer to osteogenic 
medium. Multi-cellular aggregates were observed, but not quantified, in ADI-MSC cultures 
supplemented with BMP-2 during osteogenesis. 
 
Alizarin Red Staining 
To identify cellular matrix mineralization, a 2% Alizarin Red solution was prepared to 
stain the cell layers.  Culture medium was aspirated from culture wells, the monolayers were 
washed with phosphate-buffered saline (PBS), and the cell layers were fixed with 4% 
formaldehyde at room temperature for 30 minutes. After fixation, the cell layers were washed 
three times with ddH2O. A freshly prepared 2% Alizarin Red (Sigma-Aldrich) solution (pH 4.1) 
was added to each well, ensuring that the fixed monolayers were completely submerged. After 
20 minutes, the stain was aspirated and the wells were washed 3 – 6 times with ddH2O until the 
wash solution was clear. Representative microscopic images were obtained using dry, stained 
cells (Leica Microsystems, Leica Application Suite -LAS-version 4.0.R1).  
 
RNA Isolation and Reverse Transcription-Quantitative PCR 
At appropriate collection times, culture medium was completely aspirated from the wells 
and the phenol-based dissociation agent, TRIZol® (Invitrogen Corporation, Carlsbad, CA), was 
added directly to the cell monolayers. The resultant lysates were scraped from the culture wells 
and transferred to 15 mL falcon tubes. The lysates were homogenized using an Ultra Turrax-T 25 
homogenizer (Janke & Kunkel, IKA-Labortechnik, Staufen, Germany) to completely disrupt the 
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cells. Total RNA was isolated using the phenol-chloroform dissociation, and isopropanol 
precipitation protocol recommended by the manufacturer. 
One microgram of total RNA was reverse-transcribed using Superscript First-Strand 
Synthesis System for RT-PCR (Invitrogen) to generate cDNA. Quantitative PCR was performed 
using SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA) and a BioRad iCycler (Bio-
Rad). Relative expression of BMPs-2, -4, -6, and -7 and osteoblast-specific genes alkaline 
phosphatase (ALP), runt-related transcription factor 2 (RUNX2), and Osterix (OSX) were 
derived from threshold cycle values. QPCR data were normalized to expression of the reference 
gene, elongation factor-1 alpha (EF1α). Expression for each target was calculated using the 2
-ΔΔCt 
method to measure relative fold changes in gene expression [31]. See Chapter 3 for more details. 
Primer sequences used in the qPCR reactions can be found in Table 5.1.  
 
Alkaline Phosphate Enzymatic Activity 
Cells maintained in 12-well plates were harvested with 300 μL of 2% Triton X-100 in 1X 
TE Buffer per well and the samples were stored in -20°C until further processing. After thawing, 
each sample was homogenized using IKA Labortechnik T 25 basic homogenizer (Janke & 
Kunkel GmbH and Co., Staufen, Germany) and centrifuged at 2,500 rpm for 15 minutes at 4°C.  
A working assay solution was created by a substrate tablet containing p-nitrophenyl phosphate 
dissolved into 5 mL of buffer solution using an ALP assay kit (Wako, Japan). Twenty microliters 
of each sample supernatant were assayed for ALP activity in duplicates in a transparent 96-well 
plate. A 100 μL aliquot of working assay solution was transferred into each well. Along with the 
samples, a standard of p-nitrophenol solution was run in duplicate. Each sample and standard of 
the substrate p-nitrophenyl phosphate was hydrolyzed into p-nitrophenol by ALP [32]. The 
reactions were routinely run for 10 minutes, generating a yellow product that was optically 
measured at 405 nm wavelength (FLUOstar OPTIMA, BMG, Lab Technologies). ALP 
enzymatic activity was determined on the basis of release of 1 nmol of p-nitrophenol per minute. 
The ALP activity of each sample normalized to the corresponding DNA content. The means and 





Pico Green DNA Assay 
DNA content was measured using the Pico Green DNA kit (Quanti-iT
TM
 PicoGreen 
dsDNA, Invitrogen). Samples were diluted 1:5 in 1X TE buffer (10mM Tris-HCl, 1mM EDTA, 
pH 7.5), and 100 μL of each sample was pipetted in duplicate into a black 96-well microplate. A 
standard curve was generated by serial dilutions of calf thymus DNA. One hundred microliters 
of Pico Green reagent (1 μL Pico Green reagent diluted in 200 μL of 1X TE buffer) was added to 
each sample and standard. Following a 5 minute incubation, protected from light to prevent 
reagent photo-degradation, the fluorescence was measured at 485 nm (FLUOstar OPTIMA, 
BMG, Lab Technologies). 
 
Statistical Analyses 
All data were analyzed using GraphPad Prism (GraphPad Software, INC) and expressed 
as mean + the standard error of the mean (SEM). Data were evaluated for normality using the 
Kolmogorov-Smirnov, D’Agostino and Pearson, and Shapiro-Wilk normality tests, where 
appropriate. Normally distributed data was analyzed using the tests mentioned below for each 
comparison. If normality could not be determined due to small sample size or data did not pass 
any of the normality tests, a corresponding non-parametric test was also performed. Statistical 
significant was assigned at p < 0.05. Sample sizes were n = 3 – 4 horses for all experiments. 
Significance of pair-wise comparisons was determined using t tests, while multi-variable 
analyses were carried out by ANOVA. 
Differences in the baseline mRNA expression levels of BMP-2 and BMP-4 between 
ADI- and BM-MSC were evaluated using 2-Way Analysis of Variance (ANOVA). Comparisons 
between the two cell types were performed by normalizing to ADI-MSC values. Bonferonni 
post-hoc testing was performed to compares between cell types for each ligand.  
Differences in mRNA expression levels of BMP-2 and BMP-4 in control (Cx) and 
osteogenic (OIM) cultures was evaluated using 2-Way ANOVA. Bonferonni post-hoc testing 
was performed to compare between culture treatments for each ligand.  
The effect of a BMP inhibitor and on multi-cellular aggregate counts, ALP enzymatic 
activity levels, and osteogenic gene expression in BM-MSCs was evaluated at each collection 
time point using 2-Way ANOVA. Bonferonni post-hoc tests were performed to compare BMP 
inhibitor-treated samples to osteogenic (OIM) controls.  
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The effect of BMP-2 supplementation on osteogenic gene expression in ADI-MSCs was 
evaluated using 2-Way ANOVA. Bonferonni post-hoc tests were performed to compare BMP-2 
supplemented samples to control (Cx) and osteogenic (OIM) cultures.  
 
Results 
Osteogenic BMP Ligand Expression 
Under basal conditions, expression of BMP-2 was consistently 4 – 5 times higher in BM 
cells than in ADI cells, while BMP-4 expression was 6 – 7 times higher in BM cells (Figure 
5.1). Transcript levels of BMPs-6 and -7, as reflected in Ct values at or above 30 cycles, were 
negligible in both cell types.  
After transfer into osteogenic medium, mean BMP-2 expression increased approximately 
four fold in BM cells by Day 7 and by approximately seven-fold by Day 14. Induction of BMP-4 
expression followed a similar profile (Figure 5.2). In contrast, there was little or no change in 
expression of either BMP by ADI cells, which was comparable to basal expression in BM cells.  
In summary, BM-MSCs had significantly higher baseline and osteogenesis-induced 
mRNA expression levels of BMP-2 and BMP-4 ligands compared to ADI-MSCs. 
 
BMP Inhibition in BM-MSC Osteogenic Cultures 
BMP signaling in differentiating BM-MSC cultures was inhibited by preventing 
interactions between secreted BMP ligand (recombinant human Noggin) and by inhibiting BMP 
receptor kinase function (DMH-1 and K-02288). All three inhibitors had similar effects on BM-
MSC osteogenesis. Noggin dose-dependently and significantly inhibited BM-MSC aggregation 
and matrix mineralization at later stages (Figures 5.3 & 5.4). The BMP receptor kinase 
inhibitors had similar but more potent effects on aggregation: completely inhibiting aggregate 
formation at the 500 nM concentration (data not shown).  
All three BMP inhibitors significantly suppressed ALP activity in osteogenic cultures 
(Figure 5.5). As with the aggregation responses, the BMP receptor kinase inhibitors were more 
effective than Noggin in reducing ALP activity, particularly at the highest concentration used.  
BMP signaling inhibition had no significant effect on RUNX2 expression; however, OSX 
expression was significantly reduced by the 100 and 500 nM concentrations of K-02288 (Figure 
5.6). BM-MSC responses to Noggin and DMH-1 were very similar (data not shown). BMP 
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signaling inhibition in BM-MSCs maintained in control media also produced the same effect on 
gene expression: significantly decreased OSX, but not RUNX2 (data not shown). 
In summary, BMP inhibition in BM-MSCs undergoing osteogenesis significantly 
decreased multi-cellular aggregation and Alizarin Red staining, ALP enzymatic activity, and 
OSX mRNA expression in a dose-dependent manner. 
 
BMP-2 Supplementation in ADI-MSC Osteogenic Cultures 
The impact of supplementing osteogenic ADI-MSC cultures with exogenous BMP ligand 
was assessed by adding 100 ng/ml of recombinant human BMP-2 to culture medium. There was 
little or no indication that ADI-MSCs responded to osteogenic medium by aggregating or 
secreting a mineralized matrix (Figure 5.7). BMP-2 supplementation stimulated aggregate 
formation and mineralization of aggregate matrix by Day 10, analogously to BM-MSC cultures.  
ALP expression was increased modestly in osteogenic medium. Exogenous BMP-2 did 
increase ALP expression at later time points but, due to considerable inter-donor variability, this 
was not statistically significant (Figure 5.8).  
BMP-2 supplementation did not affect RUNX2 expression in osteogenic ADI-MSC 
cultures (Figure 5.9), but it did significantly increase OSX expression at all three time points 
analyzed compared to control or osteogenic media alone (Figure 5.10). 
In summary, BMP-2 supplementation in ADI-MSCs undergoing osteogenesis 
significantly increased Alizarin Red staining and OSX mRNA expression compared to 
osteogenic media alone. Both RUNX2 and ALP mRNA expression were increased in BMP-2 
supplemented cultures, but not significantly more than osteogenic media alone due to inter-donor 
variability in responses. 
 
Discussion 
This study was designed to answer four questions related to the role of intrinsic BMP 
signaling in equine MSC osteogenesis, using the highly osteogenic cells expanded from bone 
marrow aspirates and the relative non-osteogenic cells from adipose tissue as positive and 
negative biological controls, respectively, for this differentiation program. The first question 
addressed the relative expression of osteo-chondral BMP ligands in BM and ADI cells. Both 
BMP-2 and -4 were expressed at significantly higher levels in BM-MSCs than ADI-MSCs, prior 
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to exposure to any osteogenic stimulus. This differential expression persisted when third passage 
cells were transferred to osteogenic culture conditions. Both BMP-2 and -4 mRNAs were 
induced by osteogenic medium in BM-MSCs, whereas expression remained low and 
unresponsive in ADI-MSC cultures.  
The necessity for BMP signaling in BM-MSC osteogenesis was clearly confirmed, since 
competitive interference with BMP ligand binding to BMP receptor complexes through Noggin, 
and blockading BMP receptor kinase activity by DMH-1 and K-02288, had very similar and 
consistent inhibitory effects on BM-MSC aggregation, matrix mineralization (as detected by 
Alizarin Red stain retention), ALP activity, and OSX up-regulation. Of note, RUNX2 expression 
was not impacted, strongly suggesting that RUNX2 expression and induction during 
osteogenesis is not primarily regulated by the BMP pathway [33].   
In several of the osteogenic outcomes assessed in these experiments, Noggin was less 
effective in antagonizing BMP activity than the small molecule inhibitors, despite being 
administered at supra-physiological concentrations (1000 ng/ml). This could be a consequence of 
restricted penetration of the recombinant protein from the culture medium into the dense, 
multicellular aggregates that form early in the process of osteogenesis, particularly given that 
BMP ligands secreted by BM-MSCs will be immediately available at the cell surface to act in 
autocrine and paracrine signaling before the exogenous ligand-binding antagonist can intervene.  
The final series of experiments addressed the possibility that exogenous BMP ligand 
delivery can compensate for the lack of intrinsic BMP expression in ADI-MSC cultures and 
impart a ‘bone marrow-like’ osteogenic capacity to these cells. BMP-2 supplementation did 
substantially increase expression of several osteogenic characteristics in ADI-MSCs, including 
cell aggregation and matrix mineralization, consistent with its known osteogenic activities [34, 
35]. Although osteogenic medium itself increased ALP expression in ADI-MSCS, exogenous 
BMP did not consistently augment the primary response to osteogenic medium. Of note, BMP-2 
had little detectable impact on RUNX2 expression but significantly up-regulated OSX, 
suggesting that BMPs mediate OSX expression via pathways independent of RUNX2, as occurs 
developmentally and in other experimental models [36, 37]. DLX-5 is a promising candidate for 
this RUNX2-independent regulatory pathway, based on findings in murine gene deletion models 
[38, 39]. Accepting that a single concentration of BMP-2 was used in these experiments, the 
results indicate that exogenous BMP-2 ligand does improve expression of the osteogenic 
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phenotype in ADI-MSCs but does not elevate the osteogenic capacity of these cells to ‘bone 
marrow MSC’ status. The requirements for ADI-MSC chondrogenic differentiation are 
somewhat analogous, in that adipose-derived stem cell chondrogenesis is significantly increased 
by adding BMP-6 to the chondrogenic medium [40].  
  Multi-lineage phenotypic potential is a requisite characteristic of mesenchymal stem 
cells. Although the equine adipose-derived cells used in this study qualitatively expressed some 
characteristics of the osteogenic phenotype (induction of ALP and RUNX2 expression), their 
ability to undergo osteogenesis was consistently far less than that of BM-MSCs, despite BMP-2 
supplementation. Although adipose-derived stem cells have been strongly advocated for as an 
easily acquired and versatile resource for cell-based regenerative and tissue engineering 
applications [41, 42], their limited capacity for robust phenotypic differentiation will need to be 
supported by sustained co-delivery of appropriate lineage-specific growth factors.  
 
Conclusions 
The results of this study support the hypothesis that the differential osteogenic capacity of 
equine BM-MSCs and ADI-MSCs is a consequence of differences in BMP ligand expression 
and/or induction.  More generally, this outcome supports a regulatory mechanism by which BMP 
signaling determines mesenchymal stem cell lineage predispositions towards specific 
musculoskeletal lineages. The findings strongly suggest that BMP signaling acts directly through 
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Figure 5.1: Baseline BMP-2 and BMP-4 mRNA Expression in  
ADI- and BM-MSCs 
 
Figure 5.1: Relative mRNA expression of BMP-2 and BMP-4 in undifferentiated adipose (ADI) 
and bone marrow (BM) derived MSCs. Asterisks (*) indicate a significant difference between 




Figure 5.2: Osteogenesis-Induced BMP-2 and BMP-4 mRNA Expression in BM-MSCs 
 
 
Figure 5.2: BMP-2 and BMP-4 induced mRNA expression in BM-MSCs evaluated at Day 7 and 
Day 14 post-osteogenic induction. “Cx” = control media, and “OIM” = osteogenic media. 
Dashed lines represent the approximate relative expression in ADI-MSC cultures. Asterisks (*) 
indicate a significant difference between media types (* p < 0.05). Evaluated with 2-Way 




Figure 5.3: Effect of BMP Inhibition in BM-MSCs in Osteogenic Media: 




Figure 5.3: Representative 4X magnification images of Day 3, 7, and 10 post-osteogenic induction multi-cellular aggregation and 
Alizarin Red staining in BM-MSCs maintained in control (Cx) or osteogenic (OIM) media, +/- recombinant human Noggin 
(rhNoggin) at 10, 100, or 1000 ng/ml. 
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Figure 5.4: Effect of BMP Inhibition in BM-MSCs in Osteogenic Media: 
Multi-Cellular Aggregate Counts 
 
Figure 5.4: Effect of BMP inhibition with recombinant human Noggin on multi-cellular 
aggregate formation at Day 7 and Day 10 post-osteogenic induction in BM-MSCs. “Cx” = 
control media, and “OIM” = osteogenic media. The number of aggregates per low power field 
(LPF) was assessed at ten random locations. Asterisks (*) indicate a significant decrease in 
aggregate counts compared to OIM alone (* p < 0.05). Evaluated with 2-Way ANOVA at each 
time point, n = 10, p < 0.05.  
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Figure 5.5: Effect of BMP Inhibition in BM-MSCs in Osteogenic Media: 
Alkaline Phosphatase (ALP) Enzymatic Activity 
 
 
Figure 5.5: Effect of BMP inhibition with recombinant human Noggin, DMH-1, and K-02288 on 
alkaline phosphatase (ALP) enzymatic activity in osteogenic BM-MSCs. “Cx” = control media, 
and “OIM” = osteogenic media. Asterisks (*) indicate a significant decrease in ALP enzymatic 
activity compared to OIM alone (* p < 0.05). Evaluated with 2-Way ANOVA for each inhibitor, 




Figure 5.6: Effect of BMP Inhibition in BM-MSCs in Osteogenic Media: 
Osterix mRNA Expression 
 
Figure 5.6: Effect of BMP inhibition with K-02288 on Osterix (OSX) mRNA expression at Day 
3 and Day 7 post-osteogenic induction in BM-MSCs. “Cx” = control media, and “OIM” = 
osteogenic media. Asterisks (*) indicate a significant decrease in OSX expression compared to 




Figure 5.7: BMP-2 Supplementation in ADI-MSCs: 
Representative Culture Images 
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Figure 5.7: Representative 4X magnification images of Day 5 and Day 10 post-osteogenic induction multi-cellular aggregation and 
Alizarin Red staining in ADI-MSCs. “Cx” = control media, “OIM” = osteogenic media, and “BMP-2” = recombinant human bone 




Figure 5.8: BMP-2 Supplementation in ADI-MSCs: 




Figure 5.8: ALP mRNA expression in ADI-MSCs evaluated at Days 4, 7, and 10 post-osteogenic 
induction. “Cx” = control media, “OIM” = osteogenic media, and “BMP-2” = recombinant 
human bone morphogenetic protein 2 supplemented at 100 ng/ml. Asterisks (*) indicate a 
significant effect of culture treatment on ALP expression (* p < 0.05). Evaluated with 2-Way 





Figure 5.9: BMP-2 Supplementation in ADI-MSCs: 




Figure 5.9: RUNX2 mRNA expression in ADI-MSCs evaluated at Days 4, 7, and 10 post-
osteogenic induction. “Cx” = control media, “OIM” = osteogenic media, and “BMP-2” = 
recombinant human bone morphogenetic protein 2 supplemented at 100 ng/ml. Evaluated with 2-
Way ANOVA, n = 4, p < 0.05.   
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Figure 5.10: BMP-2 Supplementation in ADI-MSCs: 




Figure 5.10: OSX mRNA expression in ADI-MSCs evaluated at Days 4, 7, and 10 post-
osteogenic induction. “Cx” = control media, “OIM” = osteogenic media, and “BMP-2” = 
recombinant human bone morphogenetic protein 2 supplemented at 100 ng/ml. Asterisks (*) 
indicate a significant effect of culture treatment on OSX expression (**** p < 0.0001). Carets 
(^) indicate a significant post-hoc test differences in OSX expression compared to controls (^ p 







Table 5.1: Primers Utilized in the qPCR Reactions 
Gene Target 
(Product Size) 
Primer Sequence & Start Site 





S: 5’ – TGGGGTGAAGGCTAATGAGG – 3’ (463) 






S: 5’ – TAACCACGCCATTGTTCAGA – 3’ 






S: 5’ – TGAGCCTTTCCAGCAAGTTT – 3’ 






S: 5’ – AGCTGGGAACACTCAGGAGA – 3’ 






S: 5’ – CAGCCTGGCTCGTTTTAGAC – 3’ 






S: 5’ – CCCGGACACAGAGACTTCAT – 3’ (277) 






S: 5’ – GGCTATGCCAATGACTACCC – 3’ (337) 






S: 5’ – CAGACCAGCAGCACTCCATA – 3’ (1135) 





Table 5.1: Sense (S) and antisense (A) sequences for primers utilized in the qPCR reactions, 
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 Conclusions and Future Directions 
The first study presented in this dissertation (Chapter 3) determined if donor status at the 
time of tissue harvest influenced subsequent in vitro viability, proliferation, and/or osteogenesis 
of adipose-derived (ADI) and bone marrow-derived (BM) MSCs collected from adult horses 
during standing sedation, general anesthesia, and shortly after euthanasia. Donor status during 
tissue collection did not impact primary cell isolate counts or cell viability/proliferation as 
evaluated by population doubling times. Of the osteogenic outcomes measured, only RUNX2 
mRNA expression in ADI-MSCs was significantly decreased at the day 5 post-induction time 
point in euthanasia-collected samples, but the effect did not persist at the later day 10 time point. 
Multi-cellular aggregation during osteogenesis, Alizarin Red staining, OSX mRNA expression, 
ALP mRNA expression, and ALP enzymatic activity were not adversely affected by donor status 
during MSC collection but differed significantly between cell types and donors. 
The overall result of this study indicates that MSCs harvested from recently deceased 
donors can serve as a viable option for allogeneic stem cells. Further research in animal models 
is necessary to identify any toxic effects of the systemic drugs administered for sedation, general 
anesthesia, and euthanasia on MSCs, and determine the ideal collection ‘window’ after death. 
This study also revealed a large degree of inter- and intra-donor variability, thus warranting 
further investigation into how various in vitro screening methods can be optimized to better 
characterize the proliferative and multi-lineage differentiation abilities of MSCs from a given 
donor and tissue source. Donor-specific factors such as age, body condition, and clinical 
condition(s) likely impacted the initial numbers of viable MSCs isolated and cell proliferative 
capacity. Therefore, determining exclusion criteria is vital when screening for potential donors. 
The second study presented in this dissertation (Chapter 4) first characterized the 
differences in the RUNX2 and OSX response axis during osteogenesis in ADI- and BM-MSCs, 
and then determined whether OSX over-expression was sufficient to improve osteogenesis in 
ADI-MSCs. Resting/baseline levels of OSX, but not RUNX2, were significantly higher in BM- 
compared to ADI-MSCs. Both cell types upregulated RUNX2 in response to osteogenic cues, 
but only BM-MSCs induced OSX. BM-MSCs showed significantly higher RUNX2 and OSX 
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induction during osteogenesis than ADI-MSCs. Over-expression of OSX in ADI-MSCs was not 
sufficient to improve multi-cellular aggregation, Alizarin Red staining, ALP mRNA expression 
and enzymatic activity, or consistently induce expression of a panel of downstream 
osteoprogenitor marker genes in either control or osteogenic conditions.  
The outcome of these experiments suggests that OSX induction influences the osteogenic 
potential of MSCs, yet OSX over-expression in less osteogenic MSC sources is not sufficient to 
improve osteogenesis. Follow-up studies should focus on characterizing epigenetic regulatory 
events that may impact differences in OSX expression profiles in MSCs from different sources. 
A comparison of the responses to RUNX2 versus OSX over-expression should also be 
performed, to identify critical non-OSX targets of RUNX2 activity. However, over-expression of 
RUNX2 or OSX alone has produced mixed results in various cell line and animal studies, likely 
because their roles during osteogenesis are precisely timed and regulated. Sustained over-
expression of RUNX2 and OSX can inhibit terminal osteoblast differentiation, so future studies 
should focus on optimizing the timing of inducible RUNX2 and/or OSX expression. There are 
also several limitations and safety concerns with using adenoviral over-expression in clinical 
scenarios, thus warranting further investigation into alternative methodologies for enhancing 
gene expression in MSCs in both in vitro cell culture and in vivo animal models.  
The third study presented in this dissertation (Chapter 5) established the importance of 
BMP signaling in determining the osteogenic potentials of MSCs. BM-MSCs were found to have 
higher baseline and osteogenesis-induced BMP-2 and -4 ligand expression compared to ADI-
MSCs, and BMP ligand secretion appears to be higher in BM-MSCs undergoing osteogenesis. 
BMP signaling was found to be necessary for osteogenesis in BM-MSCs and sufficient for 
improving osteogenic differentiation in ADI-MSCs. BMP signaling had a significant effect on 
OSX, but not RUNX2, expression in both cell types.  
This study confirmed that BMP signaling has significant influence in determining the 
osteogenic potential of MSCs from different tissue sources. The results also explain, in part, why 
OSX expression levels differed between the two cell types, and why OSX over-expression by 
itself was not sufficient for improving the osteogenic capacity of ADI-MSCs, as presented in 
Chapter 4. The BMP signaling pathway directly targets both RUNX2 and OSX, but there is 
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complex interplay from other network components and several additional signaling pathways 
that also impact osteogenic differentiation. Potential follow-up studies should include microarray 
analyses of BMP signaling network genes, characterizing epigenetic differences in BMP ligand 
and/or receptor genes between the two cell types, and quantifying how much of the OSX and 
RUNX2 expression differences were due to BMP signaling effectors using additional gene 
expression analyses and knock-down models. Recombinant BMP-2 and -7 proteins are already 
approved for use in several human orthopedic applications, yet their use is cost-prohibitive and 
can result in severe complications. Further research is therefore needed to develop controlled and 
predictable BMP signaling enhancement using gene therapy modalities and/or implantation of 
osteoinductive biomaterials.  
Globally, these studies confirmed that equine BM-MSCs have superior in vitro 
osteogenic capacity than ADI-MSCs, and identified some of the factors that play crucial roles in 
determining this difference. Adipose tissue is much more abundant and easily-accessible 
compared to bone marrow, thus making ADI-MSCs an appealing alternative to BM-MSCs for 
use in regenerative medicine. However, ADI-MSCs are not inherently equal to BM-MSCs in 
their ability to undergo osteogenic differentiation. The research presented in this dissertation 
investigated potential interventions that could prove useful for enhancing osteogenic 
differentiation of ADI-MSCs and, by extension, other progenitor populations. The ideal outcome 
of follow-up studies would be to first improve in vitro MSC screening approaches to better 
identify more robust and higher responding cell populations, and then optimize strategies for 
improving ADI-MSC osteogenesis to levels comparable to BM-MSCs. The finding that donor 
tissue from recently deceased horses yielded viable osteogenic MSCs supports the possibility of 
using cadaveric samples in research and for allogeneic stem cell banking. In conclusion, there are 
many sources available to obtain viable MSCs from adult tissues and several promising 
methodologies that can optimize their use in bone repair and regenerative medicine. 
